UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|
|
|
(Mark One) | |
|
|
☑ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2026 |
|
|
|
or |
|
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
For the transition period from _____ to _____ |
|
|
|
Commission File Number: 001-13988 |
|
Covista Inc.
(Exact name of registrant as specified in its charter)
Delaware |
36-3150143 |
(State or other jurisdiction of |
(I.R.S. Employer |
incorporation or organization) |
Identification No.) |
|
|
233 South Wacker Drive |
|
Chicago, Illinois |
60606 |
(Address of principal executive offices) |
(Zip Code) |
(312) 651-1400
(Registrant’s telephone number; including area code)
Adtalem Global Education Inc.
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock, $0.01 par value per share |
CVSA |
New York Stock Exchange |
Common stock, $0.01 par value per share |
CVSA |
NYSE Texas |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
þ |
Accelerated filer |
☐ |
|
Non-accelerated filer |
◻ |
Smaller reporting company |
☐ |
|
|
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
As of May 1, 2026, there were 34,030,887 shares of the registrant’s common stock, $0.01 par value per share outstanding.
Covista Inc.
Form 10-Q
Table of Contents
|
Page |
|
|
|
|
Item 1. |
1 |
|
|
1 |
|
|
2 |
|
|
3 |
|
|
4 |
|
|
5 |
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
26 |
Item 3. |
43 |
|
Item 4. |
44 |
|
|
|
|
Item 1. |
44 |
|
Item 1A. |
44 |
|
Item 2. |
44 |
|
Item 5. |
45 |
|
Item 6. |
45 |
|
46 |
Part I. Financial Information
Item 1. Financial Statements
Covista Inc.
Consolidated Balance Sheets
(unaudited)
(in thousands, except par value)
|
|
March 31, |
|
June 30, |
||
|
|
2026 |
|
2025 |
||
Assets: |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
146,977 |
|
$ |
199,601 |
Restricted cash |
|
|
1,862 |
|
|
1,563 |
Accounts and financing receivables, net |
|
|
175,924 |
|
|
146,189 |
Prepaid expenses and other current assets |
|
|
78,992 |
|
|
68,837 |
Total current assets |
|
|
403,755 |
|
|
416,190 |
Noncurrent assets: |
|
|
|
|
|
|
Property and equipment, net |
|
|
276,972 |
|
|
256,131 |
Operating lease assets |
|
|
201,079 |
|
|
191,194 |
Deferred income taxes |
|
|
— |
|
|
32,956 |
Intangible assets, net |
|
|
757,059 |
|
|
765,474 |
Goodwill |
|
|
961,262 |
|
|
961,262 |
Other assets, net |
|
|
137,300 |
|
|
129,145 |
Total noncurrent assets |
|
|
2,333,672 |
|
|
2,336,162 |
Total assets |
|
$ |
2,737,427 |
|
$ |
2,752,352 |
Liabilities and shareholders' equity: |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
97,261 |
|
$ |
105,017 |
Accrued payroll and benefits |
|
|
75,093 |
|
|
76,374 |
Accrued liabilities |
|
|
92,846 |
|
|
77,286 |
Deferred revenue |
|
|
276,192 |
|
|
214,091 |
Current operating lease liabilities |
|
|
35,230 |
|
|
35,159 |
Current portion of long-term debt |
|
|
3,825 |
|
|
— |
Total current liabilities |
|
|
580,447 |
|
|
507,927 |
Noncurrent liabilities: |
|
|
|
|
|
|
Long-term debt |
|
|
495,644 |
|
|
552,669 |
Long-term operating lease liabilities |
|
|
201,595 |
|
|
186,172 |
Deferred income taxes |
|
|
58,731 |
|
|
31,856 |
Other liabilities |
|
|
36,905 |
|
|
40,103 |
Total noncurrent liabilities |
|
|
792,875 |
|
|
810,800 |
Total liabilities |
|
|
1,373,322 |
|
|
1,318,727 |
Commitments and contingencies |
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
|
|
|
Common stock, $0.01 par value per share, 200,000 shares authorized; 34,023 and 35,952 shares outstanding as of March 31, 2026 and June 30, 2025, respectively |
|
|
847 |
|
|
839 |
Additional paid-in capital |
|
|
696,468 |
|
|
664,300 |
Retained earnings |
|
|
2,957,419 |
|
|
2,777,574 |
Accumulated other comprehensive loss |
|
|
(2,227) |
|
|
(2,227) |
Treasury stock, at cost, 50,720 and 47,990 shares as of March 31, 2026 and June 30, 2025, respectively |
|
|
(2,288,402) |
|
|
(2,006,861) |
Total shareholders' equity |
|
|
1,364,105 |
|
|
1,433,625 |
Total liabilities and shareholders' equity |
|
$ |
2,737,427 |
|
$ |
2,752,352 |
See accompanying Notes to Consolidated Financial Statements.
1
Covista Inc.
Consolidated Statements of Income
(unaudited)
(in thousands, except per share data)
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Revenue |
|
$ |
487,030 |
|
$ |
466,055 |
|
$ |
1,452,703 |
|
$ |
1,331,184 |
Operating cost and expense: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of educational services |
|
|
210,719 |
|
|
199,869 |
|
|
616,911 |
|
|
572,500 |
Student services and administrative expense |
|
|
184,106 |
|
|
175,167 |
|
|
542,631 |
|
|
491,141 |
Restructuring expense |
|
|
863 |
|
|
510 |
|
|
5,228 |
|
|
2,926 |
Total operating cost and expense |
|
|
395,688 |
|
|
375,546 |
|
|
1,164,770 |
|
|
1,066,567 |
Operating income |
|
|
91,342 |
|
|
90,509 |
|
|
287,933 |
|
|
264,617 |
Interest expense |
|
|
(13,629) |
|
|
(13,074) |
|
|
(35,636) |
|
|
(41,465) |
Other income, net |
|
|
232 |
|
|
1,898 |
|
|
4,422 |
|
|
6,779 |
Income from continuing operations before income taxes |
|
|
77,945 |
|
|
79,333 |
|
|
256,719 |
|
|
229,931 |
Provision for income taxes |
|
|
(19,963) |
|
|
(18,539) |
|
|
(61,504) |
|
|
(51,716) |
Income from continuing operations |
|
|
57,982 |
|
|
60,794 |
|
|
195,215 |
|
|
178,215 |
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from discontinued operations before income taxes |
|
|
(21,860) |
|
|
52 |
|
|
(20,810) |
|
|
6,216 |
Benefit from (provision for) income taxes |
|
|
5,515 |
|
|
(14) |
|
|
5,440 |
|
|
(1,578) |
(Loss) income from discontinued operations |
|
|
(16,345) |
|
|
38 |
|
|
(15,370) |
|
|
4,638 |
Net income and comprehensive income |
|
$ |
41,637 |
|
$ |
60,832 |
|
$ |
179,845 |
|
$ |
182,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
1.69 |
|
$ |
1.64 |
|
$ |
5.52 |
|
$ |
4.76 |
Discontinued operations |
|
$ |
(0.48) |
|
$ |
0.00 |
|
$ |
(0.43) |
|
$ |
0.12 |
Total basic earnings per share |
|
$ |
1.21 |
|
$ |
1.64 |
|
$ |
5.08 |
|
$ |
4.88 |
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
1.67 |
|
$ |
1.59 |
|
$ |
5.42 |
|
$ |
4.62 |
Discontinued operations |
|
$ |
(0.47) |
|
$ |
0.00 |
|
$ |
(0.43) |
|
$ |
0.12 |
Total diluted earnings per share |
|
$ |
1.20 |
|
$ |
1.59 |
|
$ |
4.99 |
|
$ |
4.74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic shares |
|
|
34,283 |
|
|
37,140 |
|
|
35,381 |
|
|
37,434 |
Diluted shares |
|
|
34,782 |
|
|
38,233 |
|
|
36,031 |
|
|
38,583 |
See accompanying Notes to Consolidated Financial Statements.
2
Covista Inc.
Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
|
|
Nine Months Ended |
||||
|
|
March 31, |
||||
|
|
2026 |
|
2025 |
||
Operating activities: |
|
|
|
|
|
|
Net income |
|
$ |
179,845 |
|
$ |
182,853 |
Loss (income) from discontinued operations |
|
|
15,370 |
|
|
(4,638) |
Income from continuing operations |
|
|
195,215 |
|
|
178,215 |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
Stock-based compensation |
|
|
31,103 |
|
|
31,181 |
Amortization and impairments to operating lease assets |
|
|
21,004 |
|
|
25,330 |
Depreciation |
|
|
32,627 |
|
|
30,267 |
Amortization of acquired intangible assets |
|
|
8,415 |
|
|
8,415 |
Amortization and write-off of debt discount and issuance costs |
|
|
6,961 |
|
|
4,995 |
Provision for bad debts |
|
|
48,853 |
|
|
46,854 |
Deferred income taxes |
|
|
65,318 |
|
|
19,994 |
Loss on disposals and impairments of property and equipment |
|
|
605 |
|
|
2,522 |
Gain on investments |
|
|
(561) |
|
|
(268) |
Changes in assets and liabilities: |
|
|
|
|
|
|
Accounts and financing receivables |
|
|
(76,271) |
|
|
(80,613) |
Prepaid expenses and other current assets |
|
|
(896) |
|
|
5,727 |
Cloud computing implementation assets |
|
|
(10,087) |
|
|
(21,959) |
Accounts payable |
|
|
(12,607) |
|
|
(9,978) |
Accrued payroll and benefits |
|
|
(1,136) |
|
|
1,406 |
Accrued liabilities |
|
|
(10,168) |
|
|
(10,449) |
Deferred revenue |
|
|
66,322 |
|
|
66,081 |
Operating lease liabilities |
|
|
(15,395) |
|
|
(17,839) |
Other assets and liabilities |
|
|
(2,888) |
|
|
(6,068) |
Net cash provided by operating activities-continuing operations |
|
|
346,414 |
|
|
273,813 |
Net cash provided by operating activities-discontinued operations |
|
|
45 |
|
|
4,394 |
Net cash provided by operating activities |
|
|
346,459 |
|
|
278,207 |
Investing activities: |
|
|
|
|
|
|
Capital expenditures |
|
|
(50,882) |
|
|
(31,337) |
Proceeds from sales of marketable securities |
|
|
2,314 |
|
|
3,120 |
Purchases of marketable securities |
|
|
(2,313) |
|
|
(2,048) |
Payment for investment in business |
|
|
(5,000) |
|
|
— |
Net cash used in investing activities |
|
|
(55,881) |
|
|
(30,265) |
Financing activities: |
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
131 |
|
|
10,008 |
Employee taxes paid on withholding shares |
|
|
(42,074) |
|
|
(12,457) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
1,305 |
|
|
922 |
Repurchases of common stock for treasury |
|
|
(239,866) |
|
|
(146,436) |
Borrowings under long-term debt obligations |
|
|
844,450 |
|
|
9,873 |
Repayments under long-term debt obligations |
|
|
(895,283) |
|
|
(109,873) |
Payment of debt issuance and extinguishment costs |
|
|
(11,566) |
|
|
— |
Net cash used in financing activities |
|
|
(342,903) |
|
|
(247,963) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(52,325) |
|
|
(21) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
201,164 |
|
|
221,202 |
Cash, cash equivalents and restricted cash at end of period |
|
$ |
148,839 |
|
$ |
221,181 |
Non-cash investing and financing activities: |
|
|
|
|
|
|
Accrued capital expenditures |
|
$ |
12,417 |
|
$ |
12,410 |
Accrued liability for repurchases of common stock |
|
$ |
— |
|
$ |
4,879 |
Accrued excise tax on share repurchases |
|
$ |
1,739 |
|
$ |
1,055 |
Accrued debt issuance and extinguishment costs |
|
$ |
421 |
|
$ |
— |
See accompanying Notes to Consolidated Financial Statements.
3
Covista Inc.
Consolidated Statements of Shareholders’ Equity
(unaudited)
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
|
|
|
|
||
|
|
Common Stock |
|
Paid-In |
|
Retained |
|
Comprehensive |
|
Treasury Stock |
|
|
|
|||||||||||
|
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Loss |
|
Shares |
|
Amount |
|
Total |
||||||||
December 31, 2024 |
|
|
83,886 |
|
$ |
839 |
|
$ |
642,975 |
|
$ |
2,662,530 |
|
$ |
(2,227) |
|
|
46,597 |
|
$ |
(1,865,207) |
|
$ |
1,438,910 |
Net income |
|
|
|
|
|
|
|
|
|
|
|
60,832 |
|
|
|
|
|
|
|
|
|
|
|
60,832 |
Stock-based compensation |
|
|
|
|
|
|
|
|
10,263 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,263 |
Net activity from stock-based compensation awards |
|
|
13 |
|
|
|
|
|
175 |
|
|
|
|
|
|
|
|
2 |
|
|
(259) |
|
|
(84) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
|
|
|
|
|
|
222 |
|
|
|
|
|
|
|
|
(4) |
|
|
173 |
|
|
395 |
Repurchases of common stock for treasury |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
792 |
|
|
(77,603) |
|
|
(77,603) |
March 31, 2025 |
|
|
83,899 |
|
$ |
839 |
|
$ |
653,635 |
|
$ |
2,723,362 |
|
$ |
(2,227) |
|
|
47,387 |
|
$ |
(1,942,896) |
|
$ |
1,432,713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2025 |
|
|
84,740 |
|
$ |
847 |
|
$ |
686,587 |
|
$ |
2,915,782 |
|
$ |
(2,227) |
|
|
50,086 |
|
$ |
(2,222,193) |
|
$ |
1,378,796 |
Net income |
|
|
|
|
|
|
|
|
|
|
|
41,637 |
|
|
|
|
|
|
|
|
|
|
|
41,637 |
Stock-based compensation |
|
|
|
|
|
|
|
|
9,571 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,571 |
Net activity from stock-based compensation awards |
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
(89) |
|
|
(89) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
|
|
|
|
|
|
310 |
|
|
|
|
|
|
|
|
(5) |
|
|
233 |
|
|
543 |
Repurchases of common stock for treasury |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
|
|
(66,353) |
|
|
(66,353) |
March 31, 2026 |
|
|
84,743 |
|
$ |
847 |
|
$ |
696,468 |
|
$ |
2,957,419 |
|
$ |
(2,227) |
|
|
50,720 |
|
$ |
(2,288,402) |
|
$ |
1,364,105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2024 |
|
|
83,194 |
|
$ |
832 |
|
$ |
611,949 |
|
$ |
2,540,509 |
|
$ |
(2,227) |
|
|
45,513 |
|
$ |
(1,781,928) |
|
$ |
1,369,135 |
Net income |
|
|
|
|
|
|
|
|
|
|
|
182,853 |
|
|
|
|
|
|
|
|
|
|
|
182,853 |
Stock-based compensation |
|
|
|
|
|
|
|
|
31,181 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,181 |
Net activity from stock-based compensation awards |
|
|
705 |
|
|
7 |
|
|
10,001 |
|
|
|
|
|
|
|
|
162 |
|
|
(12,457) |
|
|
(2,449) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
|
|
|
|
|
|
504 |
|
|
|
|
|
|
|
|
(13) |
|
|
521 |
|
|
1,025 |
Repurchases of common stock for treasury |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,725 |
|
|
(149,032) |
|
|
(149,032) |
March 31, 2025 |
|
|
83,899 |
|
$ |
839 |
|
$ |
653,635 |
|
$ |
2,723,362 |
|
$ |
(2,227) |
|
|
47,387 |
|
$ |
(1,942,896) |
|
$ |
1,432,713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2025 |
|
|
83,942 |
|
$ |
839 |
|
$ |
664,300 |
|
$ |
2,777,574 |
|
$ |
(2,227) |
|
|
47,990 |
|
$ |
(2,006,861) |
|
$ |
1,433,625 |
Net income |
|
|
|
|
|
|
|
|
|
|
|
179,845 |
|
|
|
|
|
|
|
|
|
|
|
179,845 |
Stock-based compensation |
|
|
|
|
|
|
|
|
31,103 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,103 |
Net activity from stock-based compensation awards |
|
|
801 |
|
|
8 |
|
|
123 |
|
|
|
|
|
|
|
|
320 |
|
|
(42,074) |
|
|
(41,943) |
Proceeds from stock issued under Colleague Stock Purchase Plan |
|
|
|
|
|
|
|
|
942 |
|
|
|
|
|
|
|
|
(12) |
|
|
507 |
|
|
1,449 |
Repurchases of common stock for treasury |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,422 |
|
|
(239,974) |
|
|
(239,974) |
March 31, 2026 |
|
|
84,743 |
|
$ |
847 |
|
$ |
696,468 |
|
$ |
2,957,419 |
|
$ |
(2,227) |
|
|
50,720 |
|
$ |
(2,288,402) |
|
$ |
1,364,105 |
See accompanying Notes to Consolidated Financial Statements.
4
Covista Inc.
Notes to Consolidated Financial Statements
(unaudited)
Table of Contents
Note |
|
Page |
1 |
6 |
|
2 |
6 |
|
3 |
7 |
|
4 |
7 |
|
5 |
9 |
|
6 |
10 |
|
7 |
10 |
|
8 |
11 |
|
9 |
11 |
|
10 |
14 |
|
11 |
14 |
|
12 |
15 |
|
13 |
17 |
|
14 |
20 |
|
15 |
20 |
|
16 |
22 |
|
17 |
23 |
|
18 |
24 |
5
1. Nature of Operations
In this Quarterly Report on Form 10-Q, Covista Inc. (formerly known as Adtalem Global Education Inc.), together with its subsidiaries, is collectively referred to as “Covista,” “we,” “our,” “us,” or similar references. Covista reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2026 is for our third quarter of fiscal year 2026.
Covista is the leading healthcare educator in the U.S. Our schools consist of Chamberlain University (“Chamberlain”), Walden University (“Walden”), American University of the Caribbean School of Medicine (“AUC”), Ross University School of Medicine (“RUSM”), and Ross University School of Veterinary Medicine (“RUSVM”). AUC, RUSM, and RUSVM are collectively referred to as the “medical and veterinary schools.” “Home Office” includes activities not allocated to a reportable segment. See Note 18 “Segment Information” for information on our reportable segments.
2. Summary of Significant Accounting Policies
Basis of Presentation
Our significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K”). We have prepared the accompanying unaudited consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (which are normal and recurring in nature) considered necessary for a fair presentation have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. We use the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the Notes to Consolidated Financial Statements refer to our continuing operations. Unless indicated, or the context requires otherwise, references to years refer to Covista’s fiscal years. Certain items presented in tables may not sum due to rounding. These consolidated financial statements and accompanying notes should be read in conjunction with our annual consolidated financial statements and the notes thereto included in our 2025 Form 10-K.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Standards
In December 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2025-11: “Interim Reporting (Topic 270): Narrow-Scope Improvements.” The guidance was issued to improve the guidance in Topic 270, Interim Reporting, by improving the navigability of the required interim disclosures and clarifying when that guidance is applicable. The guidance also provides additional guidance on what disclosures should be provided in interim reporting periods. The guidance is effective on a prospective or retrospective basis for financial statements issued for fiscal years beginning after December 15, 2027, and interim reporting periods within fiscal years beginning after December 15, 2028. Early adoption of the guidance is permitted. We do not expect the guidance will have a material impact on Covista’s Consolidated Financial Statements or disclosures.
In September 2025, the FASB issued ASU No. 2025-06: “Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.” The guidance was issued to modernize the accounting for software costs. The guidance is effective on a prospective, modified, or a retrospective transition approach for financial statements issued for fiscal years beginning after December 15, 2027, and interim reporting periods within those fiscal years. Early adoption of the guidance is permitted. We are currently evaluating the impact the guidance will have on Covista’s Consolidated Financial Statements.
6
In July 2025, the FASB issued ASU No. 2025-05: “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets.” The guidance was issued to provide a practical expedient to measure credit losses on current accounts receivable and current contract assets. The guidance is effective prospectively for financial statements issued for fiscal years beginning after December 15, 2025, and interim reporting periods within those fiscal years. Early adoption of the guidance is permitted. We do not expect the guidance will have a material impact on Covista’s Consolidated Financial Statements.
In November 2024, the FASB issued ASU No. 2024-03: “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” The guidance was issued to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions as well as disclosures about selling expenses. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2026 and interim reporting periods within fiscal years beginning after December 15, 2027. The amendments should be applied prospectively, however retrospective application is permitted. Early adoption of the amendments is permitted, including adoption in an interim reporting period. The amendments will expand our footnote disclosures to include a disaggregation of expenses in accordance with the amendments but will not otherwise impact Covista’s Consolidated Financial Statements.
In December 2023, the FASB issued ASU No. 2023-09: “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance was issued to enhance the transparency and decision usefulness of income tax disclosures by requiring entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2024. The amendments should be applied prospectively, however retrospective application is permitted. Early adoption of the amendments is permitted. The amendments will expand our income tax footnote disclosures to include additional information in the rate reconciliation and regarding cash taxes paid but will not otherwise impact Covista’s Consolidated Financial Statements.
We reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on our Consolidated Financial Statements or disclosures.
3. Discontinued Operations
On December 11, 2018, Covista sold DeVry University to Cogswell Education, LLC (“Cogswell”) for de minimis consideration. The purchase agreement includes an earn-out entitling Covista to payments of up to $20.0 million over a ten-year period payable based on DeVry University’s financial results. Covista received $0.5 million and $7.0 million during the second quarter of fiscal year 2026 and 2025, respectively, related to the earn-out. As of the second quarter of fiscal year 2026, we have received the full earn-out of $20.0 million.
We had a loss from discontinued operations of $16.3 million and $15.4 million in the three and nine months ended March 31, 2026, respectively. We had income from discontinued operations of $0.04 million and $4.6 million in the three and nine months ended March 31, 2025, respectively. We continue to have activity associated with ongoing litigation and settlements related to divestitures, which is classified within discontinued operations.
4. Revenue
Revenue is recognized when control of the promised goods or services is transferred to our customers (students), in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.
7
The following tables disaggregate revenue by source (in thousands):
|
|
Three Months Ended March 31, 2026 |
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
||||
Tuition and fees |
|
$ |
196,963 |
|
$ |
186,575 |
|
$ |
101,060 |
|
$ |
484,598 |
Other |
|
|
— |
|
|
— |
|
|
2,432 |
|
|
2,432 |
Total |
|
$ |
196,963 |
|
$ |
186,575 |
|
$ |
103,492 |
|
$ |
487,030 |
|
|
Nine Months Ended March 31, 2026 |
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
||||
Tuition and fees |
|
$ |
559,996 |
|
$ |
594,097 |
|
$ |
292,357 |
|
$ |
1,446,450 |
Other |
|
|
— |
|
|
— |
|
|
6,253 |
|
|
6,253 |
Total |
|
$ |
559,996 |
|
$ |
594,097 |
|
$ |
298,610 |
|
$ |
1,452,703 |
|
|
Three Months Ended March 31, 2025 |
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
||||
Tuition and fees |
|
$ |
192,592 |
|
$ |
178,418 |
|
$ |
92,597 |
|
$ |
463,607 |
Other |
|
|
— |
|
|
— |
|
|
2,448 |
|
|
2,448 |
Total |
|
$ |
192,592 |
|
$ |
178,418 |
|
$ |
95,045 |
|
$ |
466,055 |
|
|
Nine Months Ended March 31, 2025 |
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
||||
Tuition and fees |
|
$ |
541,508 |
|
$ |
511,237 |
|
$ |
270,605 |
|
$ |
1,323,350 |
Other |
|
|
— |
|
|
— |
|
|
7,834 |
|
|
7,834 |
Total |
|
$ |
541,508 |
|
$ |
511,237 |
|
$ |
278,439 |
|
$ |
1,331,184 |
In addition, see Note 18 “Segment Information” for a disaggregation of revenue by geographical region.
Performance Obligations and Revenue Recognition
Tuition and fees: The majority of revenue is derived from tuition and fees, which is recognized on a straight-line basis over the academic term as instruction is delivered.
Other: Other revenue consists of housing and other miscellaneous services. Other revenue is recognized over the period in which the applicable performance obligation is satisfied.
Arrangements for payment are agreed to prior to registration of the student’s first academic term. The majority of U.S. students obtain Title IV or other financial aid resulting in institutions receiving a significant amount of the transaction price at the beginning of the academic term. Students not utilizing Title IV or other financial aid funding may pay after the academic term is complete.
Transaction Price
Revenue, or transaction price, is measured as the amount of consideration expected to be received in exchange for transferring goods or services.
Students may receive scholarships, discounts, or refunds, which gives rise to variable consideration. The amounts of scholarships or discounts are generally applied to individual student accounts when such amounts are awarded. Therefore, the transaction price is immediately reduced directly by these scholarships or discounts from the amount of the standard tuition rate charged. Scholarships and discounts that are only applied to future tuition charged are considered a separate performance obligation if they represent a material right in accordance with ASC 606. In those instances, we defer the value of the related performance obligation associated with the future scholarship or discount based on estimates of future redemption informed by our historical experience of student persistence toward completion of study.
8
Upon withdrawal, a student may be eligible to receive a refund, or partial refund, the amount of which is dependent on the timing of the withdrawal during the academic term. If a student withdraws prior to completing an academic term, federal and state regulations and accreditation criteria permit Covista to retain a set percentage of the total tuition received from such student, which varies with, but generally equals or exceeds, the percentage of the academic term completed by such student. Payment amounts received by Covista in excess of such set percentages of tuition are refunded to the student or the appropriate funding source. For contracts with similar characteristics and historical data on refunds, the expected value method is applied in determining the variable consideration related to refunds. Estimates of Covista’s expected refunds are determined at the outset of each academic term, based upon actual refunds in previous academic terms. Reserves related to refunds are presented as refund liabilities within accrued liabilities on the Consolidated Balance Sheets. All refunds are netted against revenue during the applicable academic term.
Management reassesses collectability on a student-by-student basis throughout the period revenue is recognized. This reassessment is based upon new information and changes in facts and circumstances relevant to a student’s ability to pay. Management also reassesses collectability when a student withdraws from the institution and has unpaid tuition charges. Such unpaid charges do not meet the threshold of reasonably collectible and are recognized as revenue on a cash basis.
Contract Balances
Students are billed at the beginning of each academic term and payment is due at that time. Covista’s performance obligation is to provide educational services in the form of instruction during the academic term and to provide for any scholarships or discounts that are deemed a material right under ASC 606. As instruction is provided or the deferred value of material rights are recognized, deferred revenue is reduced. A significant portion of student payments are from Title IV financial aid and other programs and are generally received during the first month of the respective academic term. For students utilizing Covista’s credit extension programs (see Note 9 “Accounts and Financing Receivables”), payments are generally received after the academic term, and the corresponding performance obligation, is complete. When payments are received, accounts and financing receivables are reduced.
Deferred revenue within current liabilities is $276.2 million and $214.1 million as of March 31, 2026 and June 30, 2025, respectively, which includes $45.7 million and $38.1 million, respectively, related to contract liabilities associated with material rights. Deferred revenue within other noncurrent liabilities is $29.3 million and $25.0 million as of March 31, 2026 and June 30, 2025, respectively, and relates entirely to contract liabilities associated with material rights, which are expected to be earned over approximately the next four fiscal years. Revenue of $10.7 million and $202.2 million was recognized during the three and nine months ended March 31, 2026, respectively, that was included in the deferred revenue balance at the beginning of fiscal year 2026. Revenue of $6.1 million and $179.3 million was recognized during the three and nine months ended March 31, 2025, respectively, that was included in the deferred revenue balance at the beginning of fiscal year 2025.
The difference between the opening and closing balances of deferred revenue includes decreases from revenue recognized during the period, increases from charges related to the start of academic terms beginning during the period, increases from payments received related to academic terms commencing after the end of the period, and increases from recognizing additional performance obligations for material rights during the period.
5. Restructuring Expense
During the nine months ended March 31, 2026, Covista recorded restructuring expense primarily driven by workforce reductions and prior real estate consolidations at Covista’s home office. We continue to incur restructuring charges or reversals related to exited leased space from previous restructuring actions. During the nine months ended March 31, 2025, Covista recorded restructuring expense primarily driven by workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Covista’s home office. When estimating costs of exiting lease space, estimates are made which could differ materially from actual results and may result in additional restructuring charges or reversals in future periods.
9
Termination benefit charges represent severance pay and benefits for employees impacted by workforce reductions. Restructuring expense by segment was as follows (in thousands):
|
|
Three Months Ended March 31, 2026 |
|
Nine Months Ended March 31, 2026 |
||||||||||||||
|
|
Real Estate |
|
Termination |
|
Total |
|
Real Estate |
|
Termination |
|
Total |
||||||
Chamberlain |
|
$ |
— |
|
$ |
199 |
|
$ |
199 |
|
$ |
98 |
|
$ |
1,926 |
|
$ |
2,024 |
Walden |
|
|
— |
|
|
31 |
|
|
31 |
|
|
— |
|
|
460 |
|
|
460 |
Medical and Veterinary |
|
|
37 |
|
|
338 |
|
|
375 |
|
|
120 |
|
|
735 |
|
|
855 |
Home Office |
|
|
106 |
|
|
152 |
|
|
258 |
|
|
415 |
|
|
1,474 |
|
|
1,889 |
Total |
|
$ |
143 |
|
$ |
720 |
|
$ |
863 |
|
$ |
633 |
|
$ |
4,595 |
|
$ |
5,228 |
|
|
Three Months Ended March 31, 2025 |
|
Nine Months Ended March 31, 2025 |
||||||||||||||
|
|
Real Estate |
|
Termination |
|
Total |
|
Real Estate |
|
Termination |
|
Total |
||||||
Chamberlain |
|
$ |
— |
|
$ |
(23) |
|
$ |
(23) |
|
$ |
974 |
|
$ |
938 |
|
$ |
1,912 |
Medical and Veterinary |
|
|
52 |
|
|
69 |
|
|
121 |
|
|
167 |
|
|
69 |
|
|
236 |
Home Office |
|
|
172 |
|
|
240 |
|
|
412 |
|
|
538 |
|
|
240 |
|
|
778 |
Total |
|
$ |
224 |
|
$ |
286 |
|
$ |
510 |
|
$ |
1,679 |
|
$ |
1,247 |
|
$ |
2,926 |
The following table summarizes the separation and restructuring plan activity for fiscal years 2025 and 2026, for which cash payments are required (in thousands):
Liability balance as of June 30, 2024 |
|
$ |
— |
Increase in liability (termination and other charges) |
|
|
1,418 |
Reduction in liability (payments and adjustments) |
|
|
(1,418) |
Liability balance as of June 30, 2025 |
|
|
— |
Increase in liability (termination and other charges) |
|
|
4,595 |
Reduction in liability (payments and adjustments) |
|
|
(3,657) |
Liability balance as of March 31, 2026 |
|
$ |
938 |
These liability balances are recorded as accrued liabilities on the Consolidated Balance Sheets.
6. Other Income, Net
Other income, net consisted of the following (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Interest and dividend income |
|
$ |
481 |
|
$ |
2,072 |
|
$ |
3,861 |
|
$ |
6,511 |
Investment (loss) gain |
|
|
(249) |
|
|
(174) |
|
|
561 |
|
|
268 |
Other income, net |
|
$ |
232 |
|
$ |
1,898 |
|
$ |
4,422 |
|
$ |
6,779 |
Investment (loss) gain includes trading gains and losses related to the rabbi trust used to fund nonqualified deferred compensation plan obligations.
7. Income Taxes
Our effective tax rate from continuing operations was 25.6% and 24.0% in the three and nine months ended March 31, 2026, respectively, and 23.4% and 22.5% in the three and nine months ended March 31, 2025, respectively. The effective tax rate for the three months ended March 31, 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions. The effective tax rate for the nine months ended March 31, 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions and an increase in tax benefits on stock-based compensation.
10
The income tax provisions reflect the U.S. federal tax rate of 21% adjusted for taxes related to global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation.
RUSM and RUSVM each have agreements with their respective domestic governments that exempt them from local income taxation. RUSM has an exemption in Barbados until 2039 and RUSVM has an exemption in St. Kitts until 2038.
In July 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which introduced substantial changes to U.S. tax provisions. The most relevant provisions to Covista for fiscal year 2026 include allowing accelerated tax deductions for qualified property and research and development expenditures. The impacts of OBBBA were not material to the income tax provision for the three and nine months ended March 31, 2026.
8. Earnings per Share
The following table sets forth the computations of basic and diluted earnings per share and antidilutive shares (in thousands, except per share data):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
57,982 |
|
$ |
60,794 |
|
$ |
195,215 |
|
$ |
178,215 |
Discontinued operations |
|
|
(16,345) |
|
|
38 |
|
|
(15,370) |
|
|
4,638 |
Net income |
|
$ |
41,637 |
|
$ |
60,832 |
|
$ |
179,845 |
|
$ |
182,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average basic shares outstanding |
|
|
34,283 |
|
|
37,140 |
|
|
35,381 |
|
|
37,434 |
Effect of dilutive stock awards |
|
|
499 |
|
|
1,093 |
|
|
650 |
|
|
1,149 |
Weighted-average diluted shares outstanding |
|
|
34,782 |
|
|
38,233 |
|
|
36,031 |
|
|
38,583 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
1.69 |
|
$ |
1.64 |
|
$ |
5.52 |
|
$ |
4.76 |
Discontinued operations |
|
$ |
(0.48) |
|
$ |
0.00 |
|
$ |
(0.43) |
|
$ |
0.12 |
Total basic earnings per share |
|
$ |
1.21 |
|
$ |
1.64 |
|
$ |
5.08 |
|
$ |
4.88 |
Diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
1.67 |
|
$ |
1.59 |
|
$ |
5.42 |
|
$ |
4.62 |
Discontinued operations |
|
$ |
(0.47) |
|
$ |
0.00 |
|
$ |
(0.43) |
|
$ |
0.12 |
Total diluted earnings per share |
|
$ |
1.20 |
|
$ |
1.59 |
|
$ |
4.99 |
|
$ |
4.74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average antidilutive shares |
|
|
3 |
|
|
1 |
|
|
1 |
|
|
30 |
9. Accounts and Financing Receivables
Our accounts receivables relate to student balances occurring in the normal course of business. Accounts receivables have a term of less than one year and are included in accounts and financing receivables, net on our Consolidated Balance Sheets. Our financing receivables relate to credit extension programs, which provide students with payment terms in excess of one year and are included in accounts and financing receivables, net and other assets, net on our Consolidated Balance Sheets.
11
The classification of our accounts and financing receivable balances was as follows (in thousands):
|
|
March 31, 2026 |
|||||||
|
|
|
Gross |
|
|
Allowance |
|
|
Net |
Accounts receivables, current |
|
$ |
230,097 |
|
$ |
(56,841) |
|
$ |
173,256 |
Financing receivables, current |
|
|
5,387 |
|
|
(2,719) |
|
|
2,668 |
Accounts and financing receivables, current |
|
$ |
235,484 |
|
$ |
(59,560) |
|
$ |
175,924 |
|
|
|
|
|
|
|
|
|
|
Financing receivables, current |
|
$ |
5,387 |
|
$ |
(2,719) |
|
$ |
2,668 |
Financing receivables, noncurrent |
|
|
29,832 |
|
|
(7,790) |
|
|
22,042 |
Total financing receivables |
|
$ |
35,219 |
|
$ |
(10,509) |
|
$ |
24,710 |
|
|
June 30, 2025 |
|||||||
|
|
|
Gross |
|
|
Allowance |
|
|
Net |
Accounts receivables, current |
|
$ |
189,874 |
|
$ |
(46,441) |
|
$ |
143,433 |
Financing receivables, current |
|
|
5,393 |
|
|
(2,637) |
|
|
2,756 |
Accounts and financing receivables, current |
|
$ |
195,267 |
|
$ |
(49,078) |
|
$ |
146,189 |
|
|
|
|
|
|
|
|
|
|
Financing receivables, current |
|
$ |
5,393 |
|
$ |
(2,637) |
|
$ |
2,756 |
Financing receivables, noncurrent |
|
|
33,116 |
|
|
(8,757) |
|
|
24,359 |
Total financing receivables |
|
$ |
38,509 |
|
$ |
(11,394) |
|
$ |
27,115 |
Our financing receivables relate to credit extension programs available to students at Chamberlain, AUC, RUSM, and RUSVM. These credit extension programs are designed to assist students who are unable to completely cover educational costs consisting of tuition, fees, and books, and are available only after all other student financial assistance has been applied toward those purposes. In addition, AUC, RUSM, and RUSVM allow students to finance their living expenses. Repayment plans for financing agreements are developed to address the financial circumstances of the particular student. Interest charges at rates from 3.0% to 12.0% per annum accrue each month on the unpaid balance once a student withdraws or graduates from a program. Most students are required to begin repaying their obligations while they are still in school with a minimum payment level. Payments may increase upon completing or departing school.
Credit Quality
The primary credit quality indicator for our financing receivables is delinquency. Balances are considered delinquent when contractual payments on the loan become past due. We generally write-off financing receivable balances when they are at least 181 days past due. Payments are applied first to outstanding interest and then to the unpaid principal balance.
The credit quality analysis of financing receivables as of March 31, 2026 was as follows (in thousands):
|
|
Amortized Cost Basis by Origination Year |
|
|
|
||||||||||||||||
|
|
Prior |
|
2022 |
|
2023 |
|
2024 |
|
2025 |
|
2026 |
|
Total |
|||||||
1-30 days past due |
|
$ |
778 |
|
$ |
177 |
|
$ |
297 |
|
$ |
97 |
|
$ |
587 |
|
$ |
602 |
|
$ |
2,538 |
31-60 days past due |
|
|
123 |
|
|
34 |
|
|
24 |
|
|
333 |
|
|
44 |
|
|
96 |
|
|
654 |
61-90 days past due |
|
|
207 |
|
|
19 |
|
|
60 |
|
|
11 |
|
|
187 |
|
|
369 |
|
|
853 |
91-120 days past due |
|
|
37 |
|
|
7 |
|
|
51 |
|
|
11 |
|
|
323 |
|
|
15 |
|
|
444 |
121-150 days past due |
|
|
323 |
|
|
— |
|
|
59 |
|
|
38 |
|
|
38 |
|
|
4 |
|
|
462 |
Greater than 150 days past due |
|
|
3,189 |
|
|
743 |
|
|
1,260 |
|
|
1,817 |
|
|
1,390 |
|
|
11 |
|
|
8,410 |
Total past due |
|
|
4,657 |
|
|
980 |
|
|
1,751 |
|
|
2,307 |
|
|
2,569 |
|
|
1,097 |
|
|
13,361 |
Current |
|
|
6,319 |
|
|
1,412 |
|
|
2,699 |
|
|
3,472 |
|
|
4,117 |
|
|
3,839 |
|
|
21,858 |
Financing receivables, gross |
|
$ |
10,976 |
|
$ |
2,392 |
|
$ |
4,450 |
|
$ |
5,779 |
|
$ |
6,686 |
|
$ |
4,936 |
|
$ |
35,219 |
Gross write-offs |
|
$ |
625 |
|
$ |
261 |
|
$ |
1,158 |
|
$ |
806 |
|
$ |
109 |
|
$ |
— |
|
$ |
2,959 |
12
The credit quality analysis of financing receivables as of June 30, 2025 was as follows (in thousands):
|
|
Amortized Cost Basis by Origination Year |
|
|
|
||||||||||||||||
|
|
Prior |
|
2021 |
|
2022 |
|
2023 |
|
2024 |
|
2025 |
|
Total |
|||||||
1-30 days past due |
|
$ |
319 |
|
$ |
303 |
|
$ |
116 |
|
$ |
37 |
|
$ |
1,099 |
|
$ |
1,623 |
|
$ |
3,497 |
31-60 days past due |
|
|
67 |
|
|
122 |
|
|
42 |
|
|
68 |
|
|
377 |
|
|
378 |
|
|
1,054 |
61-90 days past due |
|
|
21 |
|
|
28 |
|
|
— |
|
|
255 |
|
|
27 |
|
|
72 |
|
|
403 |
91-120 days past due |
|
|
30 |
|
|
— |
|
|
— |
|
|
11 |
|
|
42 |
|
|
17 |
|
|
100 |
121-150 days past due |
|
|
44 |
|
|
10 |
|
|
— |
|
|
45 |
|
|
52 |
|
|
103 |
|
|
254 |
Greater than 150 days past due |
|
|
2,261 |
|
|
1,291 |
|
|
1,171 |
|
|
2,058 |
|
|
1,935 |
|
|
293 |
|
|
9,009 |
Total past due |
|
|
2,742 |
|
|
1,754 |
|
|
1,329 |
|
|
2,474 |
|
|
3,532 |
|
|
2,486 |
|
|
14,317 |
Current |
|
|
5,858 |
|
|
2,609 |
|
|
1,819 |
|
|
3,323 |
|
|
4,440 |
|
|
6,143 |
|
|
24,192 |
Financing receivables, gross |
|
$ |
8,600 |
|
$ |
4,363 |
|
$ |
3,148 |
|
$ |
5,797 |
|
$ |
7,972 |
|
$ |
8,629 |
|
$ |
38,509 |
Gross write-offs |
|
$ |
1,158 |
|
$ |
642 |
|
$ |
478 |
|
$ |
1,014 |
|
$ |
876 |
|
$ |
13 |
|
$ |
4,181 |
Allowance for Credit Losses
The allowance for credit losses represents an estimate of the lifetime expected credit losses inherent in our accounts and financing receivable balances as of each balance sheet date. In evaluating the collectability of our accounts and financing receivable balances, we utilize historical events, current conditions, and reasonable and supportable forecasts about the future.
For our accounts receivables, we use historical loss rates based on an aging schedule and a student’s status to determine the allowance for credit losses. As these accounts receivables are short-term in nature, management believes a student’s status provides the best credit loss estimate, while also factoring in delinquency. Students still attending classes, recently graduated, or current on payments are more likely to pay than those who are inactive due to being on a leave of absence, withdrawing from school, or not current on payments.
For our financing receivables, we use historical loss rates based on an aging schedule. As these financing receivables are based on long-term financing agreements offered by Covista, management believes that delinquency provides the best credit loss estimate. As the financing receivable balances become further past due, it is less likely we will receive payment, causing our estimate of credit losses to increase.
The following tables provide a roll-forward of the allowance for credit losses (in thousands):
|
|
Three Months Ended March 31, 2026 |
|
Nine Months Ended March 31, 2026 |
||||||||||||||
|
|
Accounts |
|
Financing |
|
Total |
|
Accounts |
|
Financing |
|
Total |
||||||
Beginning balance |
|
$ |
52,515 |
|
$ |
9,922 |
|
$ |
62,437 |
|
$ |
46,441 |
|
$ |
11,394 |
|
$ |
57,835 |
Write-offs |
|
|
(15,918) |
|
|
(252) |
|
|
(16,170) |
|
|
(46,585) |
|
|
(2,959) |
|
|
(49,544) |
Recoveries |
|
|
3,429 |
|
|
232 |
|
|
3,661 |
|
|
9,358 |
|
|
848 |
|
|
10,206 |
Provision for credit losses |
|
|
16,815 |
|
|
607 |
|
|
17,422 |
|
|
47,627 |
|
|
1,226 |
|
|
48,853 |
Ending balance |
|
$ |
56,841 |
|
$ |
10,509 |
|
$ |
67,350 |
|
$ |
56,841 |
|
$ |
10,509 |
|
$ |
67,350 |
|
|
Three Months Ended March 31, 2025 |
|
Nine Months Ended March 31, 2025 |
||||||||||||||
|
|
Accounts |
|
Financing |
|
Total |
|
Accounts |
|
Financing |
|
Total |
||||||
Beginning balance |
|
$ |
36,752 |
|
$ |
13,059 |
|
$ |
49,811 |
|
$ |
35,336 |
|
$ |
12,558 |
|
$ |
47,894 |
Write-offs |
|
|
(13,441) |
|
|
(962) |
|
|
(14,403) |
|
|
(43,311) |
|
|
(3,335) |
|
|
(46,646) |
Recoveries |
|
|
2,941 |
|
|
115 |
|
|
3,056 |
|
|
7,725 |
|
|
772 |
|
|
8,497 |
Provision for credit losses |
|
|
17,931 |
|
|
204 |
|
|
18,135 |
|
|
44,433 |
|
|
2,421 |
|
|
46,854 |
Ending balance |
|
$ |
44,183 |
|
$ |
12,416 |
|
$ |
56,599 |
|
$ |
44,183 |
|
$ |
12,416 |
|
$ |
56,599 |
13
10. Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
|
|
|
|
March 31, |
|
June 30, |
||
|
|
Useful Life |
|
2026 |
|
2025 |
||
Land |
|
- |
|
$ |
31,776 |
|
$ |
31,776 |
Buildings and improvements |
|
10 - 31 years |
|
|
204,915 |
|
|
202,240 |
Leasehold improvements |
|
Shorter of asset useful life or lease term |
|
|
140,951 |
|
|
120,603 |
Furniture and equipment |
|
3 - 8 years |
|
|
118,692 |
|
|
104,708 |
Software |
|
3 - 5 years |
|
|
120,112 |
|
|
113,565 |
Construction in progress |
|
- |
|
|
32,977 |
|
|
24,983 |
Property and equipment, gross |
|
|
|
|
649,423 |
|
|
597,875 |
Accumulated depreciation |
|
|
|
|
(372,451) |
|
|
(341,744) |
Property and equipment, net |
|
|
|
$ |
276,972 |
|
$ |
256,131 |
11. Leases
We determine if a contract contains a lease at inception. We have entered into operating leases for academic sites, housing facilities, and office space which expire at various dates through December 2042, most of which include options to terminate for a fee or extend the leases for an additional five-year period. The lease term includes the noncancelable period of the lease, as well as any periods for which we are reasonably certain to exercise extension options. We account for lease and non-lease components (e.g., common-area maintenance costs) as a single lease component for all operating leases. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. We have not entered into any finance leases.
Operating lease assets represent our right to use an underlying asset during the lease term. Operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Operating lease assets are adjusted for any prepaid or accrued lease payments, lease incentives, initial direct costs, and impairments. Our incremental borrowing rate is utilized in determining the present value of the lease payments based upon the information available at the commencement date. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. Operating lease expense is recognized on a straight-line basis over the lease term.
As of March 31, 2026, we entered into one additional operating lease that has not yet commenced. The lease is expected to commence during the fourth quarter of fiscal year 2026, has a 17-year lease term, and will result in an additional operating lease asset and operating lease liability of approximately $4.1 million.
The components of lease cost were as follows (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Operating lease cost |
|
$ |
12,486 |
|
$ |
11,712 |
|
$ |
37,063 |
|
$ |
33,822 |
Sublease income |
|
|
— |
|
|
(1,260) |
|
|
(2,002) |
|
|
(4,054) |
Total lease cost |
|
$ |
12,486 |
|
$ |
10,452 |
|
$ |
35,061 |
|
$ |
29,768 |
14
Maturities of lease liabilities as of March 31, 2026 were as follows (in thousands):
|
|
Operating |
|
Fiscal Year |
|
Leases |
|
2026 (remaining) |
|
$ |
12,266 |
2027 |
|
|
50,308 |
2028 |
|
|
49,026 |
2029 |
|
|
42,165 |
2030 |
|
|
39,769 |
Thereafter |
|
|
205,738 |
Total lease payments |
|
|
399,272 |
Less: lease incentives not yet received |
|
|
(36,916) |
Less: imputed interest |
|
|
(125,531) |
Present value of lease liabilities |
|
$ |
236,825 |
Lease term and discount rate were as follows:
|
|
March 31, |
|
|
|
2026 |
|
Weighted-average remaining operating lease term (years) |
|
|
8.7 |
Weighted-average operating lease discount rate |
|
|
7.7% |
Supplemental disclosures of cash flow information related to leases were as follows (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Cash paid for amounts in the measurement of operating lease liabilities (net of sublease and lease incentive receipts) |
|
$ |
11,668 |
|
$ |
9,388 |
|
$ |
27,819 |
|
$ |
25,673 |
Operating lease assets obtained in exchange for operating lease liabilities |
|
$ |
18,189 |
|
$ |
20,903 |
|
$ |
30,889 |
|
$ |
47,040 |
12. Goodwill and Intangible Assets
Goodwill balances by reportable segment were as follows (in thousands):
|
|
March 31, |
|
June 30, |
||
|
|
2026 |
|
2025 |
||
Chamberlain |
|
$ |
4,716 |
|
$ |
4,716 |
Walden |
|
|
651,052 |
|
|
651,052 |
Medical and Veterinary |
|
|
305,494 |
|
|
305,494 |
Total |
|
$ |
961,262 |
|
$ |
961,262 |
Indefinite-lived intangible assets consisted of the following (in thousands):
|
|
March 31, |
|
June 30, |
||
|
|
2026 |
|
2025 |
||
Title IV eligibility and accreditations |
|
$ |
611,100 |
|
$ |
611,100 |
Trade name |
|
|
141,760 |
|
|
141,760 |
Total |
|
$ |
752,860 |
|
$ |
752,860 |
15
Amortizable intangible assets consisted of the following (in thousands):
|
|
March 31, 2026 |
|
June 30, 2025 |
|
|
||||||||
|
|
Gross Carrying |
|
Accumulated |
|
Gross Carrying |
|
Accumulated |
|
Weighted-Average |
||||
|
|
Amount |
|
Amortization |
|
Amount |
|
Amortization |
|
Amortization Period |
||||
Curriculum |
|
$ |
56,091 |
|
$ |
(51,892) |
|
$ |
56,091 |
|
$ |
(43,477) |
|
5 Years |
Total |
|
$ |
56,091 |
|
$ |
(51,892) |
|
$ |
56,091 |
|
$ |
(43,477) |
|
|
Curriculum is a finite-lived intangible asset that is amortized on a straight-line basis. Curriculum amortization expense was $2.8 million and $8.4 million in the three and nine months ended March 31, 2026, respectively, and $2.8 million and $8.4 million in the three and nine months ended March 31, 2025, respectively. Future amortization expense on finite-lived intangible assets, by reporting unit, is expected to be as follows (in thousands):
Fiscal Year |
|
Walden |
|
2026 (remaining) |
|
$ |
2,805 |
2027 |
|
|
1,394 |
Total |
|
$ |
4,199 |
Indefinite-lived intangible assets related to trade names and Title IV eligibility and accreditations are not amortized, as there are no legal, regulatory, contractual, economic, or other factors that limit the useful life of these intangible assets to the reporting entity.
Goodwill and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31.
Covista has five reporting units, which are Chamberlain, Walden, AUC, RUSM, and RUSVM. These reporting units constitute components for which discrete financial information is available and regularly reviewed by segment management. We have the option to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is determined that the reporting unit fair value is more likely than not less than its carrying value, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the reporting unit’s fair value. If the carrying value of a reporting unit containing the goodwill exceeds the fair value of that reporting unit, an impairment loss is recognized equal to the difference between the carrying value of the reporting unit and its fair value, not to exceed the carrying value of goodwill. We also have the option to perform a qualitative assessment to test indefinite-lived intangible assets for impairment by determining whether it is more likely than not that the indefinite-lived intangible assets are impaired. If it is determined that the indefinite-lived intangible asset is more likely than not impaired, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the indefinite-lived intangible assets. If the carrying value of the indefinite-lived intangible assets exceeds their fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value.
During the third quarter of fiscal year 2026, Covista performed an assessment to determine whether there were indicators of a triggering event which could indicate the carrying value of the reporting units may not be supported by the fair value. No indicators of a triggering event for potential impairment were noted in the third quarter of fiscal year 2026.
If economic conditions deteriorate or operating performance of our reporting units does not meet expectations such that we revise our long-term forecasts, we may recognize impairments of goodwill and other intangible assets in future periods.
16
13. Debt
Long-term debt consisted of the following senior secured credit facilities (in thousands):
|
|
March 31, |
|
June 30, |
||
|
|
2026 |
|
2025 |
||
Term Loan B |
|
$ |
510,000 |
|
$ |
153,333 |
Senior Secured Notes due 2028 |
|
|
— |
|
|
404,950 |
Total principal |
|
|
510,000 |
|
|
558,283 |
Unamortized debt discount and issuance costs |
|
|
(10,531) |
|
|
(5,614) |
Total long-term debt |
|
|
499,469 |
|
|
552,669 |
Less current portion |
|
|
(3,825) |
|
|
— |
Long-term debt |
|
$ |
495,644 |
|
$ |
552,669 |
Scheduled future maturities of long-term debt were as follows (in thousands):
|
|
Maturity |
|
Fiscal Year |
|
Payments |
|
2026 (remaining) |
|
$ |
— |
2027 |
|
|
5,100 |
2028 |
|
|
5,100 |
2029 |
|
|
5,100 |
2030 |
|
|
5,100 |
Thereafter |
|
|
489,600 |
Total |
|
$ |
510,000 |
Credit Agreement
On August 12, 2021, in connection with the Walden acquisition, Covista entered into a credit agreement (the “Credit Agreement”) that provided for (1) a $850.0 million senior secured term loan (“Term Loan B”) with a maturity date of August 12, 2028 and (2) a $400.0 million senior secured revolving loan facility (“Revolver”) with a maturity date of August 12, 2026. We refer to the Term Loan B and Revolver collectively as the “Credit Facility.”
Term Loan B
Prior to January 26, 2024, borrowings under the Term Loan B bore interest at a rate per annum equal to, at our option, SOFR plus an applicable margin ranging from 4.00% to 4.50%, subject to a SOFR floor of 0.75%, or an alternate base rate (“ABR”) plus an applicable margin ranging from 3.00% to 3.50% depending on Covista’s net first lien leverage ratio for such period.
On January 26, 2024, we entered into Amendment No. 2 to Credit Agreement, which resulted in a 0.50% reduction in our Term Loan B interest rate margin. From January 26, 2024 through August 21, 2024, borrowings under the Term Loan B bore interest at a rate per annum equal to, at our option, SOFR plus an applicable margin ranging from 3.50% to 4.00%, subject to a SOFR floor of 0.75%, or an ABR plus an applicable margin ranging from 2.50% to 3.00% depending on Covista’s net first lien leverage ratio for such period.
On August 21, 2024, we entered into Amendment No. 3 to Credit Agreement, which resulted in a further 0.75% reduction in our Term Loan B interest rate margin and removed the leverage-based pricing grid. From August 21, 2024 through March 2, 2026, borrowings under the Term Loan B bore interest at a rate per annum equal to, at our option, SOFR plus 2.75%, subject to a SOFR floor of 0.75%, or an ABR plus 1.75%.
We made Term Loan B prepayments of $396.7 million, $100.0 million, $50.0 million, $50.0 million, $100.0 million, and $50.0 million on March 11, 2022, September 22, 2022, November 22, 2022, January 26, 2024, January 17, 2025, and October 29, 2025, respectively, resulting in a principal amount of $103.3 million as of March 1, 2026. On March 2, 2026, we entered into Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement (the “Term Loan B Amendment”) to incur new term loans under Term Loan B in an aggregate principal amount of $510.0 million with a maturity date of March 2, 2033.
17
The Term Loan B Amendment was treated as a debt extinguishment of the previously outstanding $103.3 million principal amount of Term Loan B and the issuance of a new Term Loan B with an aggregate principal amount of $510.0 million. This resulted in a loss on debt extinguishment of $1.3 million within interest expense in the Consolidated Statements of Income in the three and nine months ended March 31, 2026 related to the write-off of unamortized debt discount and issuance costs associated with the previously outstanding $103.3 million principal amount of Term Loan B.
As of March 2, 2026, borrowings under the Term Loan B bear interest at a rate per annum equal to, at our option, SOFR plus 2.25%, subject to a SOFR floor of 0.75%, or an ABR plus 1.25%. The Term Loan B requires quarterly installment payments of $1.275 million beginning on September 30, 2026. As of March 31, 2026, the principal amount of the Term Loan B was $510.0 million and had an interest rate of 5.92%, which approximated the effective interest rate.
Revolver
On August 6, 2025, we entered into Amendment No. 4 to Credit Agreement and Incremental Assumption Agreement (the “Revolver Amendment”) to (i) increase available commitments under our revolving facility by $100.0 million (resulting in aggregate outstanding commitments of $500.0 million under the revolving facility after giving effect to the Revolver Amendment) and (ii) extend the maturity and commitment termination date of our revolving facility to August 6, 2030. Letters of credit may be issued under the Revolver in an aggregate amount of up to $500.0 million. Any letters of credit issued would reduce available capacity.
Borrowings under the Revolver bear interest at a rate per annum equal to SOFR plus an applicable margin ranging from 2.25% to 3.00% or an ABR plus an applicable margin ranging from 1.25% to 2.00% depending on Covista’s net first lien leverage ratio for such period.
The Credit Agreement requires payment of a commitment fee equal to 0.25% of the unused portion of the Revolver. The commitment fee expense is recorded within interest expense in the Consolidated Statements of Income. There were no borrowings or repayments under the Revolver during the nine months ended March 31, 2025. During the nine months ended March 31, 2026, we had total borrowings and repayments of $337.0 million under the Revolver, resulting in no outstanding borrowings as of March 31, 2026. As of March 31, 2026, the Revolver had $500.0 million of available capacity.
Senior Secured Notes due 2028
On March 1, 2021, Covista issued $800.0 million aggregate principal amount of 5.50% Senior Secured Notes due 2028 (the “Notes”), which mature on March 1, 2028, pursuant to an indenture, dated as of March 1, 2021 (the “Indenture”), by and between Covista and U.S. Bank National Association, as trustee and notes collateral agent. The Notes were sold within the U.S. only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the U.S. to non-U.S. persons in reliance on Regulation S under the Securities Act.
On April 11, 2022, we repaid $373.3 million of Notes at a price equal to 100% of the principal amount of the Notes. During June 2022, we repurchased on the open market an additional $20.8 million of Notes at a price equal to approximately 90% of the principal amount and subsequently retired this debt. During the first quarter of fiscal year 2023, we repurchased on the open market an additional $0.9 million of Notes at a price equal to approximately 92% of the principal amount and subsequently retired this debt. On March 2, 2026, we repaid the remaining $405.0 million outstanding principal amount of the Notes at a redemption price equal to 100% of the principal amount. With this debt repayment, the Indenture was fully satisfied and discharged in accordance with its terms and Covista and the subsidiary guarantors party thereto have no further obligations under the Indenture. As a result, the debt repayment was treated as a debt extinguishment. This resulted in a loss on debt extinguishment of $2.6 million within interest expense in the Consolidated Statements of Income in the three and nine months ended March 31, 2026 related to the write-off of unamortized debt issuance costs and certain third-party transaction costs.
18
Debt Discount and Issuance Costs
The $50.0 million Term Loan B prepayment on October 29, 2025 and the repayment of the remaining $103.3 million principal amount on the original Term Loan B on March 2, 2026 resulted in a loss on debt extinguishment of $1.3 million and $1.9 million recorded within interest expense in the Consolidated Statements of Income in the three and nine months ended March 31, 2026, respectively, related to the write-off of unamortized debt discount and issuance costs. The issuance of a new Term Loan B on March 2, 2026 with a principal amount of $510.0 million was issued at a price of 99.5% of its principal amount, resulting in an original issue discount of 0.5%. In connection with the issuance of the Term Loan B on March 2, 2026, we capitalized $10.7 million of new debt discount and issuance costs, which are presented as a direct deduction from the face amount of the debt and are amortized as interest expense over a seven-year period from the date of the Term Loan B Amendment.
The $405.0 million Notes repayment on March 2, 2026 resulted in a loss on debt extinguishment of $2.5 million recorded within interest expense in the Consolidated Statements of Income in the three and nine months ended March 31, 2026 related to the write-off of unamortized debt issuance costs.
The debt issuance costs related to the Revolver are classified as other assets, net on the Consolidated Balance Sheets. In connection with the Revolver Amendment on August 6, 2025, we wrote-off $0.3 million of previously capitalized debt issuance costs as a loss on debt extinguishment within interest expense in the Consolidated Statements of Income during the nine months ended March 31, 2026, and capitalized $3.8 million of new debt issuance costs. All newly capitalized debt issuance costs and unamortized debt issuance costs prior to the Revolver Amendment are amortized as interest expense over a five-year period from the date of the Revolver Amendment.
The following table summarizes the unamortized debt discount and issuance costs activity for the nine months ended March 31, 2026 (in thousands):
|
|
Term Loan B |
|
Notes |
|
Revolver |
|
Total |
||||
Unamortized debt discount and issuance costs as of June 30, 2025 |
|
$ |
2,356 |
|
$ |
3,258 |
|
$ |
2,299 |
|
$ |
7,913 |
Amortization of debt discount and issuance costs |
|
|
(543) |
|
|
(792) |
|
|
(925) |
|
|
(2,260) |
Debt discount and issuance costs write-off |
|
|
(1,940) |
|
|
(2,466) |
|
|
(295) |
|
|
(4,701) |
Capitalized debt discount and issuance costs |
|
|
10,658 |
|
|
— |
|
|
3,770 |
|
|
14,428 |
Unamortized debt discount and issuance costs as of March 31, 2026 |
|
$ |
10,531 |
|
$ |
— |
|
$ |
4,849 |
|
$ |
15,380 |
Interest Expense
Interest expense consisted of the following (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Term Loan B interest expense |
|
$ |
3,625 |
|
$ |
3,031 |
|
$ |
8,453 |
|
$ |
13,333 |
Notes interest expense |
|
|
3,774 |
|
|
5,568 |
|
|
14,910 |
|
|
16,704 |
Revolver interest expense |
|
|
166 |
|
|
— |
|
|
412 |
|
|
— |
Loss on debt extinguishment |
|
|
3,828 |
|
|
1,738 |
|
|
4,810 |
|
|
1,738 |
Amortization of debt discount and issuance costs |
|
|
688 |
|
|
1,031 |
|
|
2,260 |
|
|
3,257 |
Letters of credit fees |
|
|
1,212 |
|
|
1,460 |
|
|
3,788 |
|
|
5,807 |
Other |
|
|
336 |
|
|
246 |
|
|
1,003 |
|
|
626 |
Total |
|
$ |
13,629 |
|
$ |
13,074 |
|
$ |
35,636 |
|
$ |
41,465 |
Covenants and Guarantees
The Credit Agreement contains customary covenants, including restrictions on our restricted subsidiaries’ ability to merge and consolidate with other companies, incur indebtedness, grant liens or security interest on assets, make acquisitions, loans, advances or investments, or sell or otherwise transfer assets.
19
Obligations under the Credit Agreement are secured by a first-priority lien on substantially all of the assets of Covista and certain of its domestic wholly-owned subsidiaries. The Credit Agreement contains customary events of default for facilities of this type. If an event of default under the Credit Agreement occurs and is continuing, the commitments thereunder may be terminated and the principal amount outstanding thereunder, together with all accrued and unpaid interest and other amounts owed thereunder, may be declared immediately due and payable.
With respect to the Revolver, the terms of the Credit Agreement require Covista to maintain a Total Net Leverage Ratio (as defined in the Credit Agreement) equal to or less than 3.25 to 1.00. Covista was in compliance with the Credit Agreement debt covenants as of March 31, 2026.
Off-Balance Sheet Arrangements
As of March 31, 2026, Covista had $202.6 million in surety-backed letters of credit outstanding in favor of the U.S. Department of Education (“ED”) with an expiration date of January 31, 2027. The letters of credit represent 10% of the consolidated Title IV funds Covista’s institutions received during fiscal year 2025.
As of March 31, 2026, Covista had $76.9 million of surety bonds to satisfy certain state regulatory requirements for licensure.
14. Share Repurchases
On January 19, 2024, we announced that the Board of Directors (the “Board”) authorized Covista’s fourteenth share repurchase program, which allowed Covista to repurchase up to $300.0 million of its common stock through January 16, 2027. On May 5, 2025, Covista completed its fourteenth share repurchase program. On May 6, 2025, we announced that the Board authorized Covista’s fifteenth share repurchase program, which allowed Covista to repurchase up to $150.0 million of its common stock through May 6, 2028. On December 10, 2025, Covista completed its fifteenth share repurchase program. On December 15, 2025, we announced that the Board authorized Covista’s sixteenth share repurchase program, which allows Covista to repurchase up to $750.0 million of its common stock through December 15, 2028. Covista made share repurchases under its share repurchase programs as follows (in thousands, except shares and per share data):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Total number of share repurchases |
|
|
637,538 |
|
|
791,420 |
|
|
2,421,920 |
|
|
1,724,810 |
Total cost of share repurchases |
|
$ |
65,691 |
|
$ |
77,603 |
|
$ |
238,188 |
|
$ |
149,032 |
Average price paid per share |
|
$ |
103.04 |
|
$ |
98.06 |
|
$ |
98.35 |
|
$ |
86.40 |
As of March 31, 2026, $661.8 million of authorized share repurchases remained under the sixteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. These repurchases may be made through open market purchases, accelerated share repurchases, privately negotiated transactions, or otherwise. Repurchases will be funded through available cash balances and ongoing business operating cash generation and may be suspended or discontinued at any time. Shares of stock repurchased under the programs are held as treasury shares. Repurchases under our share repurchase programs reduce the weighted-average number of shares of common stock outstanding for basic and diluted earnings per share calculations.
15. Stock-Based Compensation
Covista’s current stock-based incentive plan is its Fourth Amended and Restated Incentive Plan of 2013, which is administered by the Compensation Committee of the Board. Under the plan, employees and Board members are eligible to receive stock options, restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”), and other forms of stock awards. As of March 31, 2026, 1,119,299 shares of common stock were available for future issuance under this plan.
Stock-based compensation expense is recognized on a straight-line basis over the requisite service period. We account for forfeitures of unvested awards in the period they occur. Covista issues new shares of common stock to satisfy stock option exercises, RSU vests, and PSU vests.
20
Stock-based compensation expense is included in student services and administrative expense in the Consolidated Statements of Income. There was no capitalized stock-based compensation cost as of March 31, 2026 and June 30, 2025.
Stock Options
Beginning in fiscal year 2023, the Compensation Committee of the Board determined to no longer grant stock options. Prior to fiscal year 2023, we granted stock options generally with a four-year graded vesting from the grant date and expire ten years from the grant date. The following table summarizes stock option activity for the nine months ended March 31, 2026:
|
|
|
|
|
|
Weighted-Average |
|
|
||
|
|
Number of |
|
|
|
Remaining |
|
Aggregate |
||
|
|
Stock |
|
Weighted-Average |
|
Contractual Life |
|
Intrinsic Value |
||
|
|
Options |
|
Exercise Price |
|
(in years) |
|
(in thousands) |
||
Outstanding as of June 30, 2025 |
|
275,238 |
|
$ |
38.05 |
|
|
|
|
|
Exercised |
|
(3,624) |
|
|
35.83 |
|
|
|
|
|
Outstanding as of March 31, 2026 |
|
271,614 |
|
|
38.08 |
|
4.7 |
|
$ |
20,960 |
Exercisable as of March 31, 2026 |
|
271,614 |
|
$ |
38.08 |
|
4.7 |
|
$ |
20,960 |
The fair value of stock options that vested during the nine months ended March 31, 2026 and 2025 was $0.6 million and $1.3 million, respectively. As of March 31, 2026, all stock options have been vested and therefore there is no remaining unrecognized stock-based compensation expense related to unvested stock options. The total intrinsic value of stock options exercised for the nine months ended March 31, 2026 and 2025 was $0.4 million and $10.6 million, respectively.
RSUs
We grant RSUs generally with a three-year graded vesting from the grant date. We also grant RSUs to our Board members with a one-year cliff vest from the grant date. The fair value per share of RSUs is the closing market price of our common stock on the grant date. The following table summarizes RSU activity for the nine months ended March 31, 2026:
|
|
|
|
Weighted-Average |
|
|
|
Number of |
|
Grant Date |
|
|
|
RSUs |
|
Fair Value |
|
Unvested as of June 30, 2025 |
|
529,969 |
|
$ |
59.41 |
Granted |
|
157,435 |
|
|
97.35 |
Vested |
|
(309,775) |
|
|
51.55 |
Forfeited |
|
(30,156) |
|
|
79.88 |
Unvested as of March 31, 2026 |
|
347,473 |
|
$ |
81.84 |
The weighted-average grant date fair value per share of RSUs granted in the nine months ended March 31, 2026 and 2025 was $97.35 and $88.99, respectively. The grant date fair value of RSUs that vested during the nine months ended March 31, 2026 and 2025 was $16.0 million and $14.0 million, respectively. As of March 31, 2026, $16.0 million of unrecognized stock-based compensation expense related to unvested RSUs is expected to be recognized over a remaining weighted-average period of 1.8 years.
PSUs
We grant PSUs with an approximate three-year cliff vest from the grant date. The fair value per share of PSUs is the closing market price of our common stock on the grant date. We estimate the number of shares that will vest under our PSU awards when recognizing stock-based compensation expense for each reporting period. The final number of shares that vest under our PSUs is based on metrics approved by the Compensation Committee of the Board.
21
The following table summarizes PSU activity for the nine months ended March 31, 2026:
|
|
|
|
Weighted-Average |
|
|
|
Number of |
|
Grant Date |
|
|
|
PSUs |
|
Fair Value |
|
Unvested as of June 30, 2025 |
|
614,000 |
|
$ |
57.20 |
Incremental PSUs granted based on achievement of metrics |
|
196,416 |
|
|
42.03 |
Granted |
|
255,252 |
|
|
96.86 |
Vested |
|
(487,721) |
|
|
41.83 |
Forfeited |
|
(33,051) |
|
|
65.03 |
Unvested as of March 31, 2026 |
|
544,896 |
|
$ |
83.60 |
The weighted-average grant date fair value per share of PSUs granted in the nine months ended March 31, 2026 and 2025 was $96.86 and $89.74, respectively. The grant date fair value of PSUs that vested during the nine months ended March 31, 2026 and 2025 was $20.4 million and $2.8 million, respectively. As of March 31, 2026, $28.0 million of unrecognized stock-based compensation expense related to unvested PSUs is expected to be recognized over a remaining weighted-average period of 1.2 years.
16. Fair Value Measurements
Fair value is defined under GAAP as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or a liability. The following fair value hierarchy prioritizes the inputs in valuation methodologies used to measure fair value:
Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 – Unobservable inputs for the asset or liability. These fair value measurements require significant judgment.
The valuation methodologies used for our assets and liabilities measured at fair value and their classification in the valuation hierarchy are described below.
The carrying value of our cash, cash equivalents, and restricted cash approximates fair value because of their short-term nature and is classified as Level 1.
Covista maintains a rabbi trust with investments in stock and bond mutual funds to fund obligations under our nonqualified deferred compensation plan. The fair value of the investments in the rabbi trust included in prepaid expenses and other current assets on the Consolidated Balance Sheets as of March 31, 2026 and June 30, 2025 was $14.1 million and $12.8 million, respectively. These investments are recorded at fair value based upon quoted market prices using Level 1 inputs.
The carrying value of the credit extension programs, which approximates their fair value, is included in accounts and financing receivables, net and other assets, net on the Consolidated Balance Sheets as of March 31, 2026 and June 30, 2025 of $24.7 million and $27.1 million, respectively, and is classified as Level 2. See Note 9 “Accounts and Financing Receivables” for additional information on these credit extension programs.
Covista has a nonqualified deferred compensation plan for highly compensated employees and its Board members. The participant’s “investments” are in a hypothetical portfolio of investments which are tracked by an administrator. Changes in the fair value of the nonqualified deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. Total liabilities under the plan included in accrued liabilities on the Consolidated Balance Sheets as of March 31, 2026 and June 30, 2025 were $14.5 million and $13.5 million, respectively.
22
The fair value of the nonqualified deferred compensation obligation is classified as Level 2 because its inputs are derived principally from observable market data by correlation to the hypothetical portfolio of investments.
As of March 31, 2026 and June 30, 2025, the principal amount of our Term Loan B was $510.0 million and $153.3 million, respectively, with a fair value as of those dates of $511.0 million and $153.8 million, respectively. The valuation of the Term Loan B was based upon quoted market prices in a non-active market and is classified as Level 2. As of June 30, 2025, the principal amount of our Notes was $405.0 million, with a fair value of $402.8 million. The valuation of the Notes was based upon quoted market prices and is classified as Level 1. See Note 13 “Debt” for additional information on our Term Loan B and Notes.
During the second quarter of fiscal year 2026, we made a $5.0 million investment in a business. We do not have the ability to exercise significant influence over the investee and therefore have recorded the investment as an equity investment without readily determinable fair value within other assets, net on the Consolidated Balance Sheets. We will adjust the carrying value of this equity investment for observable price changes and impairments with changes in the measurement recognized through net income.
Covista has elected not to measure any assets or liabilities at fair value other than those required to be measured at fair value on a recurring basis. Assets measured at fair value on a nonrecurring basis include goodwill, intangible assets, and assets of businesses where the long-term value of the operations are deemed to be impaired. Goodwill and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually or more frequently if circumstances arise indicating potential impairment. This impairment review was most recently completed as of May 31, 2025. See Note 12 “Goodwill and Intangible Assets” for additional information on the impairment review, including valuation techniques and assumptions.
17. Commitments and Contingencies
Covista is subject to lawsuits, administrative proceedings, regulatory reviews, and investigations associated with financial assistance programs and other matters arising in the conduct of its business and certain of these matters are discussed below. Descriptions of certain matters from prior SEC filings may not be carried forward in this report to the extent we believe such matters no longer are required to be disclosed or there has not been, to our knowledge, significant activity relating to them. As of March 31, 2026, we adequately reserved for matters that management has determined a loss is probable and that loss can be reasonably estimated. For those matters for which we have not recorded an accrual, their possible impact on Covista’s business, financial condition, or results of operations, cannot be predicted at this time. The continued defense, resolution, or settlement of any of the following matters could require us to expend significant resources and could have a material adverse effect on our business, financial condition, results of operations, and cash flows, and result in the imposition of significant restrictions on us and our ability to operate.
As previously disclosed, pursuant to the terms of the Stock Purchase Agreement (“SPA”) by and between Covista and Cogswell, dated as of December 4, 2017, as amended, Covista sold DeVry University to Cogswell and Covista agreed to indemnify DeVry University for certain losses up to $340.0 million (the “Liability Cap”). Covista has previously disclosed DeVry University related matters that have consumed a portion of the Liability Cap.
In late January 2024 and early February 2024, ED sent notices to Chamberlain, RUSM, RUSVM, and Walden that it had received Borrower Defense to Repayment (“BDR”) applications filed by students between June 23, 2022 and November 15, 2022, which ED subsequently sent to each institution for awareness and optional response. Without a similar notice, in June 2025, AUC also received BDR claims that had been filed during the same 2022 timeframe. Each application seeks forgiveness of federal student loans made to these students. In the notices received, ED indicated that: (1) the notification was occurring prior to any substantive review of the application as well as its adjudication; (2) it would send the applications to each institution in batches of 500 per week; (3) it is optional for institutions to respond to the applications; and (4) not responding will result in no negative inference by ED. ED has also explained that it will separately decide whether to seek recoupment on any approved claim and that any recoupment actions ED chooses to initiate will have their own notification and response processes, which include an opportunity to provide additional evidence by the applicable institution. ED has indicated that an institution will learn of ED’s determination to forgive student loans only if it approves a BDR application and ED seeks recoupment. As of March 31, 2026, AUC, Chamberlain, RUSM, RUSVM, and Walden respectively have received 381, 3,144, 1,958, 2,013, and 7,804 BDR claims. Each institution has responded or will respond to all applications received; they believe that none properly stated an eligible claim for loan forgiveness.
23
To date, none of Covista’s institutions have received an ED notice of BDR application approvals or recoupment intent.
18. Segment Information
We present three reportable segments as follows:
Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.
Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.
These segments are consistent with the method by which Covista’s Chief Operating Decision Maker (“CODM”) evaluates performance and allocates resources. Covista’s CODM is our Chief Executive Officer. Our measure of segment profitability utilized by our CODM is adjusted operating income. Our CODM uses this measure to assess the operating results and performance of our segments, perform analytical comparisons to budget, and allocate resources to each segment during monthly operating reviews and annual budget process. Adjusted operating income excludes Home Office expense, restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs because these are not associated with the ongoing operations of the segments. “Home Office” includes activities not allocated to a reportable segment and is included to reconcile segment results to the Consolidated Financial Statements. Total assets by segment are not presented as our CODM does not review or allocate resources based on segment assets. The accounting policies of the segments are the same as those described in Note 2 “Summary of Significant Accounting Policies.”
24
Summary financial information by reportable segment is as follows (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Chamberlain |
|
$ |
196,963 |
|
$ |
192,592 |
|
$ |
559,996 |
|
$ |
541,508 |
Walden |
|
|
186,575 |
|
|
178,418 |
|
|
594,097 |
|
|
511,237 |
Medical and Veterinary |
|
|
103,492 |
|
|
95,045 |
|
|
298,610 |
|
|
278,439 |
Consolidated |
|
$ |
487,030 |
|
$ |
466,055 |
|
$ |
1,452,703 |
|
$ |
1,331,184 |
Cost of educational services: |
|
|
|
|
|
|
|
|
|
|
|
|
Chamberlain |
|
$ |
84,939 |
|
$ |
83,397 |
|
$ |
254,205 |
|
$ |
237,120 |
Walden |
|
|
70,278 |
|
|
62,105 |
|
|
201,763 |
|
|
177,799 |
Medical and Veterinary |
|
|
55,502 |
|
|
54,367 |
|
|
160,943 |
|
|
157,581 |
Other segment expenses(1): |
|
|
|
|
|
|
|
|
|
|
|
|
Chamberlain |
|
$ |
64,129 |
|
$ |
61,702 |
|
$ |
198,465 |
|
$ |
186,760 |
Walden |
|
|
73,921 |
|
|
68,314 |
|
|
215,424 |
|
|
196,644 |
Medical and Veterinary |
|
|
26,488 |
|
|
22,757 |
|
|
74,358 |
|
|
66,688 |
Adjusted operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Chamberlain |
|
$ |
47,895 |
|
$ |
47,493 |
|
$ |
107,326 |
|
$ |
117,628 |
Walden |
|
|
42,376 |
|
|
47,999 |
|
|
176,910 |
|
|
136,794 |
Medical and Veterinary |
|
|
21,502 |
|
|
17,921 |
|
|
63,309 |
|
|
54,170 |
Total segment adjusted operating income |
|
|
111,773 |
|
|
113,413 |
|
|
347,545 |
|
|
308,592 |
Reconciliation to Consolidated Financial Statements: |
|
|
|
|
|
|
|
|
|
|
|
|
Home Office expense |
|
|
(9,525) |
|
|
(8,047) |
|
|
(28,937) |
|
|
(25,930) |
Restructuring expense |
|
|
(863) |
|
|
(510) |
|
|
(5,228) |
|
|
(2,926) |
Amortization of acquired intangible assets |
|
|
(2,805) |
|
|
(2,805) |
|
|
(8,415) |
|
|
(8,415) |
Litigation reserve |
|
|
— |
|
|
— |
|
|
— |
|
|
5,550 |
Asset impairments |
|
|
— |
|
|
(6,442) |
|
|
— |
|
|
(6,442) |
Strategic advisory costs |
|
|
(7,238) |
|
|
(5,100) |
|
|
(17,032) |
|
|
(5,100) |
Debt modification costs |
|
|
— |
|
|
— |
|
|
— |
|
|
(712) |
Consolidated operating income |
|
|
91,342 |
|
|
90,509 |
|
|
287,933 |
|
|
264,617 |
Interest expense |
|
|
(13,629) |
|
|
(13,074) |
|
|
(35,636) |
|
|
(41,465) |
Other income, net |
|
|
232 |
|
|
1,898 |
|
|
4,422 |
|
|
6,779 |
Consolidated income from continuing operations before income taxes |
|
$ |
77,945 |
|
$ |
79,333 |
|
$ |
256,719 |
|
$ |
229,931 |
Depreciation: |
|
|
|
|
|
|
|
|
|
|
|
|
Chamberlain |
|
$ |
6,027 |
|
$ |
5,350 |
|
$ |
17,108 |
|
$ |
16,184 |
Walden |
|
|
2,075 |
|
|
1,951 |
|
|
6,089 |
|
|
5,428 |
Medical and Veterinary |
|
|
3,109 |
|
|
2,785 |
|
|
8,936 |
|
|
8,098 |
Home Office |
|
|
166 |
|
|
188 |
|
|
494 |
|
|
557 |
Consolidated |
|
$ |
11,377 |
|
$ |
10,274 |
|
$ |
32,627 |
|
$ |
30,267 |
Amortization of acquired intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Walden |
|
$ |
2,805 |
|
$ |
2,805 |
|
$ |
8,415 |
|
$ |
8,415 |
Consolidated |
|
$ |
2,805 |
|
$ |
2,805 |
|
$ |
8,415 |
|
$ |
8,415 |
| (1) | Other segment expenses for each reportable segment include student services and administrative related expenses. |
25
Covista conducts its educational operations in the U.S., Barbados, St. Kitts, and St. Maarten. Revenue and long-lived assets by geographic area are as follows (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Revenue by geographic area: |
|
|
|
|
|
|
|
|
|
|
|
|
Domestic operations |
|
$ |
383,538 |
|
$ |
371,010 |
|
$ |
1,154,093 |
|
$ |
1,052,745 |
Barbados, St. Kitts, and St. Maarten |
|
|
103,492 |
|
|
95,045 |
|
|
298,610 |
|
|
278,439 |
Consolidated |
|
$ |
487,030 |
|
$ |
466,055 |
|
$ |
1,452,703 |
|
$ |
1,331,184 |
|
|
March 31, |
|
June 30, |
||
|
|
2026 |
|
2025 |
||
Long-lived assets by geographic area: |
|
|
|
|
|
|
Domestic operations |
|
$ |
346,697 |
|
$ |
308,190 |
Barbados, St. Kitts, and St. Maarten |
|
|
131,354 |
|
|
139,135 |
Consolidated |
|
$ |
478,051 |
|
$ |
447,325 |
No one customer accounted for more than 10% of Covista’s consolidated revenue for all periods presented.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report. It should also be read in conjunction with our consolidated financial statements and the related Management’s Discussion and Analysis of Financial Condition and Results of Operation as contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K), the Cautionary Disclosure Regarding Forward-Looking Statements, the Risk Factors included in the 2025 Form 10-K, and the Financial Aid and Legislative and Regulatory Requirements disclosures set forth in this report. Covista reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2026 is for our third quarter of fiscal year 2026.
Throughout this MD&A, we sometimes use information derived from the Consolidated Financial Statements and the notes thereto but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain of these items are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. See the “Non-GAAP Financial Measures and Reconciliations” section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures.
Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands. Discussions throughout this MD&A are based on continuing operations unless otherwise noted.
Available Information
We use our website (www.covista.com) as a routine channel of distribution of company information, including press releases, presentations, and supplemental information, as one means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, you should monitor our website in addition to following press releases, SEC filings, and public conference calls and webcasts. You can receive notifications of new information posted on our investor relations website in real time by signing up for email alerts. You may also access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, as well as other reports relating to us that are filed with or furnished to the SEC, free of charge in the investor relations section of our website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The content of the websites mentioned above is not incorporated into and should not be considered a part of this report.
26
Segments
We present three reportable segments as follows:
Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.
Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice.
Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.
“Home Office” includes activities not allocated to a reportable segment. Financial and descriptive information about Covista’s reportable segments is presented in Note 18 “Segment Information” to the Consolidated Financial Statements.
Third Quarter Highlights
Financial and operational highlights for the third quarter of fiscal year 2026 include:
| ● | Covista revenue increased 4.5%, or $21.0 million, to $487.0 million in the third quarter of fiscal year 2026 compared to the prior year period driven by increased revenue across all of our segments. Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. |
| ● | Net income decreased 31.6%, or $19.2 million, to $41.6 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The net income decrease was also driven by a loss from discontinued operations and increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives, partially offset by a reduction in asset impairments. |
| ● | Diluted earnings per share decreased 24.5%, or $0.39, to $1.20 in the third quarter of fiscal year 2026 compared to the prior year period driven by the decrease in net income, partially offset by lower diluted shares due to share repurchases. |
| ● | Adjusted net income decreased 5.8%, or $4.2 million, to $69.0 million in the third quarter of fiscal year 2026 compared to the prior year period. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted net income decrease was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. |
| ● | Adjusted earnings per share increased 3.1%, or $0.06, to $1.98 in the third quarter of fiscal year 2026 compared to the prior year period driven by lower diluted shares due to share repurchases, partially offset by the decrease in adjusted net income. |
| ● | For the January 2026 and March 2026 sessions, total student enrollment at Chamberlain decreased 0.7% and increased 0.5%, respectively, compared to the same sessions last year. |
| ● | As of March 31, 2026, total student enrollment at Walden increased 12.3% compared to March 31, 2025. |
27
| ● | For the January 2026 semester, total student enrollment at the medical and veterinary schools increased 4.1% compared to the same semester last year. |
| ● | On March 2, 2026, we entered into Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement (the “Term Loan B Amendment”) to incur new term loans under Term Loan B in an aggregate principal amount of $510.0 million with a maturity date of March 2, 2033. In addition, on March 2, 2026, we repaid the previously outstanding $103.3 million principal amount of Term Loan B and the remaining $405.0 million outstanding principal amount of the Senior Secured Notes due 2028. See Note 13 “Debt” to the Consolidated Financial Statements for additional information. |
| ● | Covista repurchased a total of 637,538 shares of its common stock under its share repurchase programs at an average cost of $103.04 per share during the third quarter of fiscal year 2026. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. |
Results of Operations
Revenue
The following tables present revenue by segment detailing the changes from the prior year periods (in thousands):
|
|
Three Months Ended March 31, 2026 |
|
||||||||||
|
|
Chamberlain |
|
Walden (1) |
|
Medical and |
|
Consolidated (1) |
|
||||
Fiscal year 2025 |
|
$ |
192,592 |
|
$ |
178,418 |
|
$ |
95,045 |
|
$ |
466,055 |
|
Growth |
|
|
4,371 |
|
|
8,157 |
|
|
8,447 |
|
|
20,975 |
|
Fiscal year 2026 |
|
$ |
196,963 |
|
$ |
186,575 |
|
$ |
103,492 |
|
$ |
487,030 |
|
% change from prior year |
|
|
2.3 |
% |
|
4.6 |
% |
|
8.9 |
% |
|
4.5 |
% |
|
|
Nine Months Ended March 31, 2026 |
|
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
|
||||
Fiscal year 2025 |
|
$ |
541,508 |
|
$ |
511,237 |
|
$ |
278,439 |
|
$ |
1,331,184 |
|
Growth |
|
|
18,488 |
|
|
82,860 |
|
|
20,171 |
|
|
121,519 |
|
Fiscal year 2026 |
|
$ |
559,996 |
|
$ |
594,097 |
|
$ |
298,610 |
|
$ |
1,452,703 |
|
% change from prior year |
|
|
3.4 |
% |
|
16.2 |
% |
|
7.2 |
% |
|
9.1 |
% |
| (1) | Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden segment revenue would have increased 14.7%, or $26.2 million, to $204.6 million and consolidated revenue would have increased 8.4%, or $39.0 million, to $505.0 million. |
Chamberlain
Chamberlain Student Enrollment:
|
|
Fiscal Year 2026 |
|
|
|
||||||||
Session |
|
July 2025 |
|
Sept. 2025 |
|
Nov. 2025 |
|
Jan. 2026 |
|
Mar. 2026 |
|
|
|
Total students |
|
37,697 |
|
39,846 |
|
39,278 |
|
40,145 |
|
40,767 |
|
|
|
% change from prior year |
|
4.5 |
% |
2.2 |
% |
(1.0) |
% |
(0.7) |
% |
0.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year 2025 |
|
||||||||||
Session |
|
July 2024 |
|
Sept. 2024 |
|
Nov. 2024 |
|
Jan. 2025 |
|
Mar. 2025 |
|
May 2025 |
|
Total students |
|
36,061 |
|
38,987 |
|
39,691 |
|
40,445 |
|
40,564 |
|
38,891 |
|
% change from prior year |
|
12.1 |
% |
11.7 |
% |
11.5 |
% |
8.7 |
% |
6.8 |
% |
5.8 |
% |
Chamberlain revenue increased 2.3%, or $4.4 million, to $197.0 million in the third quarter and increased 3.4%, or $18.5 million, to $560.0 million in the first nine months of fiscal year 2026 compared to the prior year periods. The increase in revenue in the third quarter of fiscal year 2026 was driven by higher tuition rates and increased enrollment in the March session as increases in pre-licensure nursing program enrollment more than offset declines in post-licensure nursing program enrollment.
28
The increase in revenue in the first nine months of fiscal year 2026 was driven by higher tuition rates and enrollment. Enrollment increased in pre-licensure nursing programs in all fiscal year 2026 sessions; however, enrollment has declined in post-licensure nursing programs during fiscal year 2026. Chamberlain is achieving pre-licensure growth by optimizing investments in student enrollment and experience while leveraging scale through a national footprint with in-person and online curriculum delivery modalities. Management is focused on optimizing marketing and enrollment operations to address post-licensure enrollment.
Tuition Rates:
Tuition rates in the current fiscal year increased in January 2026 compared to the prior fiscal year for the Bachelor of Science in Nursing (“BSN”) onsite and online degree, Master of Science in Nursing (“MSN”), Master of Social Work (“MSW”) and Master of Public Health (“MPH”) online degree programs. The average increase across all of these programs was approximately 3.3% from the prior year.
Walden
Walden Student Enrollment:
|
|
Fiscal Year 2026 |
|
|
|
||||
|
|
Sept. 30, |
|
Dec. 31, |
|
Mar. 31, |
|
|
|
Period |
|
2025 |
|
2025 |
|
2026 |
|
|
|
Total students |
|
52,216 |
|
52,435 |
|
54,474 |
|
|
|
% change from prior year |
|
13.6 |
% |
13.0 |
% |
12.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year 2025 |
|
||||||
|
|
Sept. 30, |
|
Dec. 31, |
|
Mar. 31, |
|
June 30, |
|
Period |
|
2024 |
|
2024 |
|
2025 |
|
2025 |
|
Total students |
|
45,979 |
|
46,399 |
|
48,526 |
|
48,116 |
|
% change from prior year |
|
12.2 |
% |
13.2 |
% |
13.5 |
% |
15.0 |
% |
Walden total student enrollment represents those students attending instructional sessions as of the dates identified above. Walden revenue increased 4.6%, or $8.2 million, to $186.6 million in the third quarter and increased 16.2%, or $82.9 million, to $594.1 million in the first nine months of fiscal year 2026 compared to the prior year periods, driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student. Walden revenue for the third quarter of fiscal year 2026 was impacted by the shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Walden’s improved enrollment has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning® competency-based programs.
Tuition Rates:
Tuition rates for Walden programs, including general education are charged on a per credit hour basis that varies based on the nature of the program. For other programs such as those with a subscription-based learning modality, tuition is charged on a per term basis. Students are also charged program and clinical fees depending on the specific programs. Some programs require students to attend residencies, skills labs, and pre-practicum labs, for which tuition is charged per event. In most programs, these tuition rates, event charges, and fees increased by approximately 2.6% from the prior year.
29
Medical and Veterinary
Medical and Veterinary Student Enrollment:
|
|
Fiscal Year 2026 |
|
|
|
||
Semester |
|
Sept. 2025 |
|
Jan. 2026 |
|
|
|
Total students |
|
5,297 |
|
5,344 |
|
|
|
% change from prior year |
|
2.4 |
% |
4.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year 2025 |
|
||||
Semester |
|
Sept. 2024 |
|
Jan. 2025 |
|
May 2025 |
|
Total students |
|
5,174 |
|
5,133 |
|
4,773 |
|
% change from prior year |
|
(0.7) |
% |
1.2 |
% |
1.0 |
% |
Medical and Veterinary revenue increased 8.9%, or $8.4 million, to $103.5 million in the third quarter and increased 7.2%, or $20.2 million, to $298.6 million in the first nine months of fiscal year 2026 compared to the prior year periods, driven by an increase in enrollment and higher tuition rates. Management continues to focus on increasing enrollment and driving operational effectiveness, specifically around academic support and the enrollment experience.
Tuition Rates:
| ● | Effective for semesters beginning in September 2025, tuition rates and administrative fees for the basic sciences and clinical rotation portions of AUC’s medical program increased 4.5% from the prior academic year. |
| ● | Effective for semesters beginning in September 2025, tuition rates and administrative fees for the basic sciences and clinical rotation portions of RUSM’s medical program increased 4.5% and 4.6%, respectively, from the prior academic year. |
| ● | Effective for semesters beginning in September 2025, tuition rates for the pre-clinical and clinical curriculum of RUSVM’s veterinary program increased 3.0% from the prior academic year. |
Cost of Educational Services
The cost of educational services expense category includes expenses related to the cost of faculty and staff who support educational operations, facilities, adjunct faculty, supplies, housing, bookstore, other educational materials, student education-related support activities, and provision for bad debts. The following tables present cost of educational services by segment detailing the changes from the prior year periods (in thousands):
|
|
Three Months Ended March 31, 2026 |
|
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
|
||||
Fiscal year 2025 |
|
$ |
83,397 |
|
$ |
62,105 |
|
$ |
54,367 |
|
$ |
199,869 |
|
Cost increase |
|
|
1,542 |
|
|
8,173 |
|
|
1,135 |
|
|
10,850 |
|
Fiscal year 2026 |
|
$ |
84,939 |
|
$ |
70,278 |
|
$ |
55,502 |
|
$ |
210,719 |
|
% change from prior year |
|
|
1.8 |
% |
|
13.2 |
% |
|
2.1 |
% |
|
5.4 |
% |
|
|
Nine Months Ended March 31, 2026 |
|
||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Consolidated |
|
||||
Fiscal year 2025 |
|
$ |
237,120 |
|
$ |
177,799 |
|
$ |
157,581 |
|
$ |
572,500 |
|
Cost increase |
|
|
17,085 |
|
|
23,964 |
|
|
3,362 |
|
|
44,411 |
|
Fiscal year 2026 |
|
$ |
254,205 |
|
$ |
201,763 |
|
$ |
160,943 |
|
$ |
616,911 |
|
% change from prior year |
|
|
7.2 |
% |
|
13.5 |
% |
|
2.1 |
% |
|
7.8 |
% |
Cost of educational services increased 5.4%, or $10.9 million, to $210.7 million in the third quarter and increased 7.8%, or $44.4 million, to $616.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. The cost increase in the third quarter and first nine months of fiscal year 2026 was primarily driven by an increase in labor and other costs to support increased enrollment.
30
As a percentage of revenue, cost of educational services was 43.3% and 42.5% in the third quarter and first nine months of fiscal year 2026, respectively, compared to 42.9% and 43.0% in the prior year periods. The increase in the percentage for the third quarter of fiscal year 2026 was primarily the result of the $18.0 million impact on Walden revenue due to the shift of one academic week from the third quarter to the second quarter of fiscal year 2026. The decrease in the percentage for the first nine months of fiscal year 2026 was primarily the result of revenue growth accompanied by cost efficiencies.
Student Services and Administrative Expense
The student services and administrative expense category includes expenses related to student admissions, marketing and advertising, general and administrative, and amortization of acquired intangible assets. The following tables present student services and administrative expense by segment detailing the changes from the prior year periods (in thousands):
|
|
Three Months Ended March 31, 2026 |
|
|||||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Home Office |
|
Consolidated |
|
|||||
Fiscal year 2025 |
|
$ |
61,702 |
|
$ |
71,119 |
|
$ |
22,757 |
|
$ |
19,589 |
|
$ |
175,167 |
|
Cost increase |
|
|
2,427 |
|
|
5,607 |
|
|
3,731 |
|
|
1,478 |
|
|
13,243 |
|
Asset impairments decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(6,442) |
|
|
(6,442) |
|
Strategic advisory costs increase |
|
|
— |
|
|
— |
|
|
— |
|
|
2,138 |
|
|
2,138 |
|
Fiscal year 2026 |
|
$ |
64,129 |
|
$ |
76,726 |
|
$ |
26,488 |
|
$ |
16,763 |
|
$ |
184,106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal year 2026 % change: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost increase |
|
|
3.9 |
% |
|
7.9 |
% |
|
16.4 |
% |
|
7.5 |
% |
|
7.6 |
% |
Asset impairments decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(32.9) |
% |
|
(3.7) |
% |
Strategic advisory costs increase |
|
|
— |
|
|
— |
|
|
— |
|
|
10.9 |
% |
|
1.2 |
% |
Fiscal year 2026 % change |
|
|
3.9 |
% |
|
7.9 |
% |
|
16.4 |
% |
|
(14.4) |
% |
|
5.1 |
% |
|
|
Nine Months Ended March 31, 2026 |
|
|||||||||||||
|
|
Chamberlain |
|
Walden |
|
Medical and |
|
Home Office |
|
Consolidated |
|
|||||
Fiscal year 2025 |
|
$ |
186,760 |
|
$ |
199,509 |
|
$ |
66,688 |
|
$ |
38,184 |
|
$ |
491,141 |
|
Cost increase |
|
|
11,705 |
|
|
18,780 |
|
|
7,670 |
|
|
3,007 |
|
|
41,162 |
|
Litigation reserve impact |
|
|
— |
|
|
5,550 |
|
|
— |
|
|
— |
|
|
5,550 |
|
Asset impairments decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(6,442) |
|
|
(6,442) |
|
Strategic advisory costs increase |
|
|
— |
|
|
— |
|
|
— |
|
|
11,932 |
|
|
11,932 |
|
Debt modification costs decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(712) |
|
|
(712) |
|
Fiscal year 2026 |
|
$ |
198,465 |
|
$ |
223,839 |
|
$ |
74,358 |
|
$ |
45,969 |
|
$ |
542,631 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal year 2026 % change: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost increase |
|
|
6.3 |
% |
|
9.4 |
% |
|
11.5 |
% |
|
7.9 |
% |
|
8.4 |
% |
Litigation reserve impact |
|
|
— |
|
|
2.8 |
% |
|
— |
|
|
— |
|
|
1.1 |
% |
Asset impairments decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(16.9) |
% |
|
(1.3) |
% |
Strategic advisory costs increase |
|
|
— |
|
|
— |
|
|
— |
|
|
31.2 |
% |
|
2.4 |
% |
Debt modification costs decrease |
|
|
— |
|
|
— |
|
|
— |
|
|
(1.9) |
% |
|
(0.1) |
% |
Fiscal year 2026 % change |
|
|
6.3 |
% |
|
12.2 |
% |
|
11.5 |
% |
|
20.4 |
% |
|
10.5 |
% |
Student services and administrative expense increased 5.1%, or $8.9 million, to $184.1 million in the third quarter and increased 10.5%, or $51.5 million, to $542.6 million in the first nine months of fiscal year 2026 compared to the prior year periods. After excluding asset impairments and strategic advisory costs, student services and administrative expense increased 7.6%, or $13.2 million, in the third quarter of fiscal year 2026 compared to the prior year period. After excluding litigation reserve, asset impairments, strategic advisory costs, and debt modification costs, student services and administrative expense increased 8.4%, or $41.2 million, in the first nine months of fiscal year 2026 compared to the prior year period.
31
These increases were primarily driven by an increase in marketing expense and investments to support growth initiatives.
As a percentage of revenue, student services and administrative expense was 37.8% and 37.4% in the third quarter and first nine months of fiscal year 2026, respectively, compared to 37.6% and 36.9% in the prior year periods. The increase in the percentage for the third quarter of fiscal year 2026 was primarily the result of the $18.0 million impact on Walden revenue due to the shift of one academic week from the third quarter to the second quarter of fiscal year 2026. The increase in the percentage for the first nine months of fiscal year 2026 was primarily the result of an increase in strategic advisory costs in the current year period and a reduction in litigation reserves in the prior year period, partially offset by revenue growth in the current year period. The reduction in litigation reserves in fiscal year 2025 represented a $5.6 million receipt in the second quarter of fiscal year 2025 from a claim made for indemnification under the Membership Interest Purchase Agreement with Laureate Education, Inc.
Restructuring Expense
Restructuring expense was $0.9 million and $5.2 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $0.5 million and $2.9 million in the prior year periods. The increases in fiscal year 2026 were primarily driven by workforce reductions. In addition, we continue to incur restructuring charges or reversals related to exited leased space from previous restructuring activities.
32
Operating Income
The following table presents a reconciliation of operating income to adjusted operating income by segment (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||||||
|
|
March 31, |
|
March 31, |
||||||||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
||||||
|
|
2026 |
|
2025 |
|
$ |
|
% |
|
|
2026 |
|
2025 |
|
$ |
|
% |
|
||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
$ |
47,696 |
|
$ |
47,516 |
|
$ |
180 |
|
0.4 |
% |
|
$ |
105,302 |
|
$ |
115,716 |
|
$ |
(10,414) |
|
(9.0) |
% |
Restructuring expense |
|
|
199 |
|
|
(23) |
|
|
222 |
|
|
|
|
|
2,024 |
|
|
1,912 |
|
|
112 |
|
|
|
Adjusted operating income |
|
$ |
47,895 |
|
$ |
47,493 |
|
$ |
402 |
|
0.8 |
% |
|
$ |
107,326 |
|
$ |
117,628 |
|
$ |
(10,302) |
|
(8.8) |
% |
Operating margin |
|
|
24.2 |
% |
|
24.7 |
% |
|
|
|
|
|
|
|
18.8 |
% |
|
21.4 |
% |
|
|
|
|
|
Adjusted operating margin |
|
|
24.3 |
% |
|
24.7 |
% |
|
|
|
|
|
|
|
19.2 |
% |
|
21.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
$ |
39,540 |
|
$ |
45,194 |
|
$ |
(5,654) |
|
(12.5) |
% |
|
$ |
168,035 |
|
$ |
133,929 |
|
$ |
34,106 |
|
25.5 |
% |
Restructuring expense |
|
|
31 |
|
|
— |
|
|
31 |
|
|
|
|
|
460 |
|
|
— |
|
|
460 |
|
|
|
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
2,805 |
|
|
— |
|
|
|
|
|
8,415 |
|
|
8,415 |
|
|
— |
|
|
|
Litigation reserve |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
(5,550) |
|
|
5,550 |
|
|
|
Adjusted operating income (1) |
|
$ |
42,376 |
|
$ |
47,999 |
|
$ |
(5,623) |
|
(11.7) |
% |
|
$ |
176,910 |
|
$ |
136,794 |
|
$ |
40,116 |
|
29.3 |
% |
Operating margin |
|
|
21.2 |
% |
|
25.3 |
% |
|
|
|
|
|
|
|
28.3 |
% |
|
26.2 |
% |
|
|
|
|
|
Adjusted operating margin (1) |
|
|
22.7 |
% |
|
26.9 |
% |
|
|
|
|
|
|
|
29.8 |
% |
|
26.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
$ |
21,127 |
|
$ |
17,800 |
|
$ |
3,327 |
|
18.7 |
% |
|
$ |
62,454 |
|
$ |
53,934 |
|
$ |
8,520 |
|
15.8 |
% |
Restructuring expense |
|
|
375 |
|
|
121 |
|
|
254 |
|
|
|
|
|
855 |
|
|
236 |
|
|
619 |
|
|
|
Adjusted operating income |
|
$ |
21,502 |
|
$ |
17,921 |
|
$ |
3,581 |
|
20.0 |
% |
|
$ |
63,309 |
|
$ |
54,170 |
|
$ |
9,139 |
|
16.9 |
% |
Operating margin |
|
|
20.4 |
% |
|
18.7 |
% |
|
|
|
|
|
|
|
20.9 |
% |
|
19.4 |
% |
|
|
|
|
|
Adjusted operating margin |
|
|
20.8 |
% |
|
18.9 |
% |
|
|
|
|
|
|
|
21.2 |
% |
|
19.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home Office: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
$ |
(17,021) |
|
$ |
(20,001) |
|
$ |
2,980 |
|
14.9 |
% |
|
$ |
(47,858) |
|
$ |
(38,962) |
|
$ |
(8,896) |
|
(22.8) |
% |
Restructuring expense |
|
|
258 |
|
|
412 |
|
|
(154) |
|
|
|
|
|
1,889 |
|
|
778 |
|
|
1,111 |
|
|
|
Asset impairments |
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
Strategic advisory costs |
|
|
7,238 |
|
|
5,100 |
|
|
2,138 |
|
|
|
|
|
17,032 |
|
|
5,100 |
|
|
11,932 |
|
|
|
Debt modification costs |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
712 |
|
|
(712) |
|
|
|
Adjusted operating loss |
|
$ |
(9,525) |
|
$ |
(8,047) |
|
$ |
(1,478) |
|
(18.4) |
% |
|
$ |
(28,937) |
|
$ |
(25,930) |
|
$ |
(3,007) |
|
(11.6) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Covista: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (GAAP) (1) |
|
$ |
91,342 |
|
$ |
90,509 |
|
$ |
833 |
|
0.9 |
% |
|
$ |
287,933 |
|
$ |
264,617 |
|
$ |
23,316 |
|
8.8 |
% |
Restructuring expense |
|
|
863 |
|
|
510 |
|
|
353 |
|
|
|
|
|
5,228 |
|
|
2,926 |
|
|
2,302 |
|
|
|
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
2,805 |
|
|
— |
|
|
|
|
|
8,415 |
|
|
8,415 |
|
|
— |
|
|
|
Litigation reserve |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
(5,550) |
|
|
5,550 |
|
|
|
Asset impairments |
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
Strategic advisory costs |
|
|
7,238 |
|
|
5,100 |
|
|
2,138 |
|
|
|
|
|
17,032 |
|
|
5,100 |
|
|
11,932 |
|
|
|
Debt modification costs |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
712 |
|
|
(712) |
|
|
|
Adjusted operating income (non-GAAP) (1) |
|
$ |
102,248 |
|
$ |
105,366 |
|
$ |
(3,118) |
|
(3.0) |
% |
|
$ |
318,608 |
|
$ |
282,662 |
|
$ |
35,946 |
|
12.7 |
% |
Operating margin (GAAP) (1) |
|
|
18.8 |
% |
|
19.4 |
% |
|
|
|
|
|
|
|
19.8 |
% |
|
19.9 |
% |
|
|
|
|
|
Adjusted operating margin (non-GAAP) (1) |
|
|
21.0 |
% |
|
22.6 |
% |
|
|
|
|
|
|
|
21.9 |
% |
|
21.2 |
% |
|
|
|
|
|
| (1) | Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden adjusted operating income would have increased 25.8%, or $12.4 million, to $60.4 million and Walden adjusted operating margin would have been 29.5%. Similarly, consolidated operating income would have increased 20.8%, or $18.8 million, to $109.4 million and consolidated adjusted operating income would have increased 14.1%, or $14.9 million, to $120.3 million. Consolidated operating margin would have been 21.7% and consolidated adjusted operating margin would have been 23.8%. |
Consolidated operating income increased 0.9%, or $0.8 million, to $91.3 million in the third quarter and increased 8.8%, or $23.3 million, to $287.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The operating income increase in the third quarter of fiscal year 2026 was also driven by a reduction in asset impairments, partially offset by increases in strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
33
The operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue and a reduction in asset impairments, partially offset by a reduction in litigation reserves in the prior year period, and increases in strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Consolidated adjusted operating income decreased 3.0%, or $3.1 million, to $102.2 million in the third quarter and increased 12.7%, or $35.9 million, to $318.6 million in the first nine months of fiscal year 2026 compared to the prior year periods. While consolidated revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted operating income decrease in the third quarter of fiscal year 2026 was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. The adjusted operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Chamberlain
Segment adjusted operating income increased 0.8%, or $0.4 million, to $47.9 million in the third quarter and decreased 8.8%, or $10.3 million, to $107.3 million in the first nine months of fiscal year 2026 compared to the prior year periods. The adjusted operating income increase in the third quarter of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs of educational services, marketing expense, and investments to support growth initiatives. The adjusted operating income decrease in the first nine months of fiscal year 2026 was primarily driven by increases in labor and other costs of educational services, marketing expense, and investments to support growth initiatives, partially offset by an increase in revenue.
Walden
Segment adjusted operating income decreased 11.7%, or $5.6 million, to $42.4 million in the third quarter and increased 29.3%, or $40.1 million, to $176.9 million in the first nine months of fiscal year 2026 compared to the prior year periods. While Walden revenue increased in the third quarter of fiscal year 2026 compared to the prior year period, Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. The adjusted operating income decrease in the third quarter of fiscal year 2026 was also driven by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives. The adjusted operating income increase in the first nine months of fiscal year 2026 was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.
Medical and Veterinary
Segment adjusted operating income increased 20.0%, or $3.6 million, to $21.5 million in the third quarter and increased 16.9%, or $9.1 million, to $63.3 million in the first nine months of fiscal year 2026 compared to the prior year periods. The adjusted operating income increases in the third quarter and first nine months of fiscal year 2026 were primarily driven by an increase in revenue, partially offset by increases in investments to support initiatives to drive growth, investments in academic support, and marketing expense.
Interest Expense
Interest expense was $13.6 million and $35.6 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $13.1 million and $41.5 million in the prior year periods. The interest expense increase in the third quarter of fiscal year 2026 was primarily driven by an increase in a loss on debt extinguishment from the write-off of debt issuance costs (as discussed in Note 13 “Debt” to the Consolidated Financial Statements). The interest expense decrease in the first nine months of fiscal year 2026 was primarily driven by lower interest expense due to decreased borrowings and a lower interest rate on our Term Loan B, and lower outstanding letters of credit balances during the period, partially offset by an increase in a loss on debt extinguishment from the write-off of debt issuance costs.
34
Other Income, Net
Other income, net was $0.2 million and $4.4 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to $1.9 million and $6.8 million in the prior year periods. The decrease in the third quarter of fiscal year 2026 was primarily driven by a decrease in interest income driven by lower invested cash balances and higher investment losses. The decrease in the first nine months of fiscal year 2026 was primarily driven by a decrease in interest income driven by lower invested cash balances, partially offset by higher investment gains.
Provision for Income Taxes
Our effective income tax rate from continuing operations can differ from the 21% U.S. federal statutory rate due to several factors, including tax on global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation.
Our effective tax rate from continuing operations was 25.6% and 24.0% in the third quarter and first nine months of fiscal year 2026, respectively, and 23.4% and 22.5% in the third quarter and first nine months of fiscal year 2025, respectively. The effective tax rate for the third quarter of fiscal year 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions. The effective tax rate for the first nine months of fiscal year 2026 increased compared to the prior year period primarily due to an increase in the limitation of tax benefits on certain executive compensation, partially offset by a decrease in the percentage of earnings from operations in higher taxed jurisdictions and an increase in tax benefits on stock-based compensation.
In July 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which introduced substantial changes to U.S. tax provisions. The most relevant provisions to Covista for fiscal year 2026 include allowing accelerated tax deductions for qualified property and research and development expenditures. The impacts of OBBBA were not material to the income tax provision for the third quarter and nine months ended March 31, 2026.
Discontinued Operations
We had a loss from discontinued operations of $16.3 million and $15.4 million in the third quarter and first nine months of fiscal year 2026, respectively, compared to income of $0.04 million and $4.6 million in the prior year periods. We recorded income within discontinued operations related to the DeVry University earn-out of $0.5 million and $7.0 million in the first nine months of fiscal year 2026 and 2025, respectively. In addition, we continue to have activity associated with ongoing litigation and settlements related to divestitures, which is classified within discontinued operations.
Financial Aid
Like other higher education institutions, Covista’s institutions are dependent upon the timely receipt of federal financial aid funds. All public financial aid programs are subject to political and governmental budgetary considerations. Covista’s institutions and their students participate in a wide range of financial aid programs, including U.S. federal financial aid, state financial aid, Canadian financial aid, private loan programs, tax-favored programs, Covista-provided financial assistance, and employer-provided financial assistance. In the U.S., the Higher Education Act (as reauthorized, the “HEA”) guides the federal government’s support of postsecondary education. Changes to financial aid programs that restrict student eligibility or reduce funding levels could have a material adverse effect on Covista’s business, financial condition, results of operations, and cash flows. See Item 1A. “Risk Factors” in our 2025 Form 10-K for a discussion of student financial aid related risks.
35
Legislative and Regulatory Requirements
Government-funded financial assistance programs are governed by extensive and complex regulations in the U.S. Like any other educational institution, Covista’s institutions’ administration of these programs is periodically reviewed by regulatory agencies and is subject to audit or investigation by other authorities. Any violation could be the basis for penalties or other disciplinary action, including initiation of a suspension, limitation, or termination proceeding.
Financial Responsibility
Institutions must pass an ED financial responsibility test, also known as a “composite score,” to maintain eligibility to participate in Title IV aid programs. For Covista’s institutions, this test is calculated at the consolidated Covista level. Applying various financial elements from annual audited financial statements, the score is a composite of three ratios: an equity ratio that measures the institution’s capital resources; a primary reserve ratio that measures an institution’s ability to fund its operations from current resources; and a net income ratio that measures an institution’s ability to operate profitably. A score greater than or equal to 1.5 indicates the institution is considered financially responsible. A score less than 1.5 but greater than or equal to 1.0 is considered financially responsible but requires additional oversight. For example, an institution with a score in this range is subject to heightened cash monitoring and other participation requirements. An institution with a score of less than 1.0 is not considered financially responsible but may continue to participate in the Title IV programs under provisional certification. In addition, this lower score typically requires that the institution be subject to heightened cash monitoring requirements and post a letter of credit (equal to a minimum of 10% of the Title IV aid it received in the institution's most recent fiscal year).
Prior to fiscal year 2022, Covista’s composite score was greater than 1.5. However, on September 25, 2023, ED notified Covista that its fiscal year 2022 composite score had declined to 0.2. As previously disclosed, this was expected due to the acquisition of Walden and other transactions. ED advised that Covista’s five institutions will be permitted to continue to participate in Title IV under provisional certifications with heightened cash monitoring and continued reporting. Management does not believe these conditions will have a material adverse effect on Covista’s operations. At ED’s request, Covista maintains surety-backed letters of credit in favor of ED totaling $202.6 million representing 10% of the consolidated Title IV funds Covista’s institutions received during fiscal year 2025. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.
The financial responsibility rules include other mandatory or discretionary triggers that could require an institution to post a letter of credit. ED recently amended the financial responsibility regulation and the changes took effect July 1, 2024. The changes include additional triggers which could require additional letters of credit.
Program Participation Agreement (“PPA”)
The HEA specifies the manner in which ED reviews institutions for eligibility and certification to participate in Title IV programs. Every educational institution participating in Title IV programs must be certified to participate through a PPA and certification must be periodically renewed. Such recertification generally is required every six years, but may be required earlier, including when an institution undergoes a change in control. Institutions that violate certain ED Title IV regulations may lose eligibility to participate in Title IV programs or may only continue participation under provisional certification. ED may place an institution on provisional certification status if it finds that the institution does not fully satisfy all of the eligibility and certification standards and in certain other circumstances, such as when an institution is certified for the first time or undergoes a change in control. During the period of provisional certification, the institution must comply with any additional conditions included in the institution’s PPA. In addition, ED may more closely review an institution that is provisionally certified if it applies for recertification or approval to open a new location, add an educational program, acquire another institution, or make any other significant change. Students attending provisionally certified institutions remain eligible to receive Title IV program funds. Provisional certification status also carries fewer due process protections than full certification. If ED determines that a provisionally certified institution is unable to meet its responsibilities under its PPA, it may seek to revoke the institution’s certification to participate in Title IV programs without advance notice or opportunity for the institution to challenge the action.
In February 2026, ED provisionally recertified Chamberlain’s PPA through December 31, 2028.
36
ED provisionally recertified Walden’s Title IV PPA through December 31, 2028.
In March 2026, ED provisionally recertified AUC’s PPA through December 31, 2028.
ED last provisionally recertified RUSM’s Title IV PPA through March 31, 2025. Title IV regulations relative to the recertification process allow for an institution’s continued participation in the Title IV programs until its application is either approved or not approved, provided a materially complete application is submitted by the institution no later than 90 days prior to the expiration date in its PPA. This is true even if ED does not complete its evaluation of the application before the PPA’s expiration date. A materially complete application for RUSM’s PPA recertification was timely submitted to ED, which has allowed for RUSM’s unhampered continued access to Title IV funding after PPA expiration.
ED provisionally recertified RUSVM’s Title IV PPA through March 31, 2027.
The provisional nature of the PPAs stemmed from Covista’s composite score declining and failing to meet ED’s standards of financial responsibility as described above.
Walden, AUC, RUSM, and RUSVM’s provisional PPAs included financial requirements, such as letter of credit and heightened cash monitoring, and RUSM and RUSVM’s provisional PPAs require additional reporting. We do not believe these requirements will have a material effect on Covista’s financial condition or results of operations.
Gainful Employment
The HEA requires certificate programs at all Title IV institutions and degree programs at proprietary Title IV institutions to prepare students for gainful employment in a recognized occupation. In October 2023, ED released new Financial Value Transparency (“FVT”) and Gainful Employment (“GE”) rules effective July 1, 2024. GE programs must meet a debt-to-earnings test in which graduates’ annual debt payments must not exceed 8% of their annual earnings or 20% of their discretionary earnings. GE programs must also meet an earnings premium test in which graduates’ earnings must exceed those of a typical high school graduate. Under the regulation, programs that fail either metric must provide warnings to students and prospective students that the program is at risk of losing Title IV eligibility and programs that fail the same measure in two out of three consecutive years lose Title IV eligibility. The GE regulation also includes a transparency framework in which debt-to-earnings, earnings premium, and a wide range of other program outcomes for all Title IV programs are disclosed on a website hosted by ED. Because there are many factors and unknowns, including the earnings of program graduates, Covista is reviewing the regulation to determine what impact, if any, the regulation will have on its programs. In addition, multiple parties sought to block enforcement of the FVT/GE rule under the Administrative Procedure Act and other legal theories. On October 2, 2025, a federal district judge ruled in ED’s favor, upholding the FVT/GE rules. The decision is subject to appeal. On February 14, 2025, ED extended the institutional reporting deadline for 2023-2024 and earlier award years until September 30, 2025. The reporting deadline for the 2024-2025 award year was October 1, 2025. On July 25, 2025, ED announced its intent to establish negotiated rulemaking committees in advance of issuing draft regulations on various topics, including FVT/GE. The negotiating committee addressing FVT/GE met in December 2025 and January 2026. ED’s initial proposal includes amendments to the FVT/GE rules including elimination of debt to earnings.
Do No Harm
The recently enacted Do No Harm provisions of OBBBA provide that an undergraduate program may lose Title IV eligibility if the earnings of a programmatic cohort of its completers as defined in OBBBA are no greater than earnings of a population with a high school diploma, and a graduate or professional program may lose Title IV eligibility if the earnings of a programmatic cohort of its completers as defined in OBBBA and its implementing regulations are no greater than the earnings of a population with a bachelor’s degree, in each case for two years in a three-year period. These provisions are applicable to all Title IV participating institutions. Regulations to define how Do No Harm will be implemented, including the definition of completer, the populations to be used to measure the difference between earnings of completers and earnings of others, have yet to be promulgated. On July 25, 2025, ED announced its intent to establish negotiated rulemaking committees to implement Do No Harm and other provisions of OBBBA. The negotiating committee met in December 2025 and January 2026.
37
The 90/10 Rule
An ED regulation known as the 90/10 Rule affects only proprietary institutions participating in Title IV programs, including each of Covista’s institutions. Under this regulation, an institution that derives more than 90% of its revenue on a cash basis from Federal education assistance funds in two consecutive fiscal years loses eligibility to participate in Title IV programs. The following table shows the 90/10 rates for each Covista institution for fiscal year 2025 and fiscal year 2024. A consolidated rate for Covista is also provided even though it is not subject to 90/10 requirements.
|
|
Fiscal Year |
|
||
|
|
2025 |
|
2024 |
|
Chamberlain University |
|
70 |
% |
68 |
% |
Walden University |
|
82 |
% |
82 |
% |
American University of the Caribbean School of Medicine |
|
86 |
% |
87 |
% |
Ross University School of Medicine |
|
86 |
% |
87 |
% |
Ross University School of Veterinary Medicine |
|
77 |
% |
78 |
% |
Consolidated |
|
78 |
% |
77 |
% |
Borrower Defense to Repayment
Under the HEA, ED is authorized to specify acts or omissions of an institution that a borrower may assert as a Borrower Defense to Repayment (“BDR”) of their Title IV loans made under the Federal Direct Loan Program. The 2022 BDR regulations were scheduled to go into effect on July 1, 2023 that included a lower threshold for establishing misrepresentation, no statute of limitation for claims submission, expanded reasons to file a claim including aggressive or deceptive recruitment tactics and omission of fact, weakened due processes afforded to institutions, and reinstated provisions for group discharges. ED also included a six-year statute of limitations for recovery of funds from institutions. These changes would increase financial liability risk and reputational risk for Covista. However, the updated rules were delayed by litigation from another party and the July 2025 enactment of OBBBA, which restored the 2019 BDR regulations and delayed the 2022 regulations until July 1, 2035. Consequently, on August 8, 2025, the parties in the litigation dismissed the appeal of the preliminary injunction order, returning the merits of the case to the district court.
Liquidity and Capital Resources
Covista’s primary source of liquidity is the cash received from payments for student tuition, fees, books, and other educational materials. These payments include funds originating as financial aid from various federal and state loan and grant programs, student and family educational loans, employer educational reimbursements, scholarships, and student and family financial resources. Covista continues to provide financing options for its students, including Covista’s credit extension programs.
The pattern of cash receipts during the year is seasonal. Covista’s cash collections on accounts receivable peak at the start of each institution’s term. Accounts receivable reach their lowest level at the end of each institution’s term.
Covista’s consolidated cash and cash equivalents balance of $147.0 million and $199.6 million as of March 31, 2026 and June 30, 2025, respectively, included cash and cash equivalents held at Covista’s international operations of $3.3 million and $22.9 million as of March 31, 2026 and June 30, 2025, respectively, which is available to Covista for general corporate purposes.
Cash Flow Summary
Operating Activities
Net cash provided by operating activities from continuing operations in the nine months ended March 31, 2026 increased $72.6 million to $346.4 million, compared to $273.8 million in the prior year period. This increase was primarily driven by a $125.3 million increase in cash collected from students, a $22.9 million decrease in net legal settlement payments, a $6.8 million decrease in interest payments, and a $2.3 million decrease in income tax payments, partially offset by a $82.1 million increase in payments to employees and vendors.
38
Investing Activities
Net cash used in investing activities in the nine months ended March 31, 2026 and 2025 was $55.9 million and $30.3 million, respectively, and was primarily driven by capital expenditures of $50.9 million and $31.3 million, respectively. In addition, during the nine months ended March 31, 2026, we made a $5.0 million minority investment in a business. Capital expenditures for fiscal year 2026 primarily include information technology investments and new campus development at Chamberlain.
Financing Activities
Net cash used in financing activities in the nine months ended March 31, 2026 was $342.9 million, primarily driven by share repurchases of $239.9 million, net repayments under long-term debt obligations of $50.8 million, and employee taxes paid on withholding shares of $42.1 million. Net cash used in financing activities in the nine months ended March 31, 2025 was $248.0 million, primarily driven by share repurchases of $146.4 million and net repayments under long-term debt obligations of $100.0 million.
On December 15, 2025, we announced that the Board authorized Covista’s sixteenth share repurchase program, which allows Covista to repurchase up to $750.0 million of its common stock through December 15, 2028. As of March 31, 2026, $661.8 million of authorized share repurchases remained under the sixteenth share repurchase program. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. See Note 14 “Share Repurchases” to the Consolidated Financial Statements for additional information on our share repurchase programs.
Material Cash Requirements
Long-Term Debt – As of March 31, 2026, Covista had a Term Loan B principal amount of $510.0 million under its Credit Facility, which matures on March 2, 2033 and requires quarterly interest payments. See Note 13 “Debt” to the Consolidated Financial Statements for additional information on our Credit Facility.
As of March 31, 2026, Covista had $202.6 million of surety-backed letters of credit outstanding in favor of ED. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.
As of March 31, 2026, Covista had $76.9 million of surety bonds to satisfy certain state regulatory requirements for licensure.
In the event of unexpected market conditions or negative economic changes that could negatively affect Covista’s earnings and/or operating cash flow, our Credit Facility includes a $500.0 million revolving credit facility with available capacity of $500.0 million as of March 31, 2026.
Operating Lease Obligations – We have operating lease obligations for the minimum payments required under various lease agreements which are recorded on the Consolidated Balance Sheets. See Note 11 “Leases” to the Consolidated Financial Statements for additional information on our lease obligations.
We believe our cash flows from operations, and our existing cash balances, combined with availability under our credit facility and access to the debt markets, will provide sufficient liquidity to fund our current obligations, projected working capital requirements, capital spending, and anticipated stock repurchases for a period that includes the next twelve months as well as the next several years. However, our ability to maintain sufficient liquidity may be affected by numerous factors, many of which are outside our control.
We have engaged in and continue to engage in the review and planning of strategic alternatives to refinance or otherwise optimize our capital structure, which alternatives may include issuing debt, equity or other securities, or entering into new credit facilities. This review and planning could result in our pursuing one or more significant corporate transactions. There can be no assurance as to when or whether we will determine to pursue any such transaction, whether any such transaction will be successful, or the effects the failure to undertake any such transaction may have on our business, including our ability to achieve our operational, strategic, and financial goals.
39
Critical Accounting Estimates
There have been no material changes in our critical accounting estimates as disclosed in our 2025 Form 10-K.
Recent Accounting Pronouncements
For information regarding recent accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements.
Cautionary Disclosure Regarding Forward-Looking Statements
Certain statements contained in this Quarterly Report on Form 10-Q are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risks and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our 2025 Form 10-K and that might be contained in this Quarterly Report on Form 10-Q, which should be read in conjunction with the forward-looking statements in this Quarterly Report on Form 10-Q. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.
Non-GAAP Financial Measures and Reconciliations
We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in this Quarterly Report on Form 10-Q:
Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.
Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.
Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs.
Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs.
40
Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.
A description of special items in our non-GAAP financial measures described above are as follows:
| ● | Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense. |
| ● | Amortization of acquired intangible assets. |
| ● | Amortization of cloud computing implementation assets. |
| ● | Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs. |
| ● | Reserves related to significant litigation. |
| ● | Loss on debt extinguishment related to amendments and repayments of our Senior Secured Notes due 2028, Term Loan B, and Revolver. |
| ● | Asset impairments related to adjusting certain operating lease assets and property and equipment as a result of adjusting carrying values to fair values. |
| ● | Debt modification costs related to refinancing our Term Loan B. |
| ● | Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements related to divestitures and the earn-outs we received. |
The following tables provide a reconciliation from the most directly comparable GAAP measure to these non-GAAP financial measures. The operating income reconciliation is included in the results of operations section within this MD&A.
Net income reconciliation to adjusted net income (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Net income (GAAP) |
|
$ |
41,637 |
|
$ |
60,832 |
|
$ |
179,845 |
|
$ |
182,853 |
Restructuring expense |
|
|
863 |
|
|
510 |
|
|
5,228 |
|
|
2,926 |
Amortization of acquired intangible assets |
|
|
2,805 |
|
|
2,805 |
|
|
8,415 |
|
|
8,415 |
Strategic advisory costs |
|
|
7,238 |
|
|
5,100 |
|
|
17,032 |
|
|
5,100 |
Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs |
|
|
3,828 |
|
|
8,180 |
|
|
4,810 |
|
|
3,342 |
Income tax impact on non-GAAP adjustments (1) |
|
|
(3,676) |
|
|
(4,134) |
|
|
(8,822) |
|
|
(4,821) |
Loss (income) from discontinued operations |
|
|
16,345 |
|
|
(38) |
|
|
15,370 |
|
|
(4,638) |
Adjusted net income (non-GAAP) |
|
$ |
69,040 |
|
$ |
73,255 |
|
$ |
221,878 |
|
$ |
193,177 |
| (1) | Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
41
Diluted earnings per share reconciliation to adjusted earnings per share (shares in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
March 31, |
|
March 31, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Diluted earnings per share (GAAP) |
|
$ |
1.20 |
|
$ |
1.59 |
|
$ |
4.99 |
|
$ |
4.74 |
Effect on diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring expense |
|
|
0.02 |
|
|
0.01 |
|
|
0.15 |
|
|
0.08 |
Amortization of acquired intangible assets |
|
|
0.08 |
|
|
0.07 |
|
|
0.23 |
|
|
0.22 |
Strategic advisory costs |
|
|
0.21 |
|
|
0.13 |
|
|
0.47 |
|
|
0.13 |
Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs |
|
|
0.11 |
|
|
0.21 |
|
|
0.13 |
|
|
0.09 |
Income tax impact on non-GAAP adjustments (1) |
|
|
(0.11) |
|
|
(0.11) |
|
|
(0.24) |
|
|
(0.12) |
Loss (income) from discontinued operations |
|
|
0.47 |
|
|
(0.00) |
|
|
0.43 |
|
|
(0.12) |
Adjusted earnings per share (non-GAAP) |
|
$ |
1.98 |
|
$ |
1.92 |
|
$ |
6.16 |
|
$ |
5.01 |
Diluted shares |
|
|
34,782 |
|
|
38,233 |
|
|
36,031 |
|
|
38,583 |
| (1) | Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements. |
42
Reconciliation to adjusted EBITDA (in thousands):
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||||||
|
|
March 31, |
|
March 31, |
||||||||||||||||||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
|
|
|
|
|
|
|
Increase/(Decrease) |
|
||||||
|
|
2026 |
|
2025 |
|
$ |
|
% |
|
|
2026 |
|
2025 |
|
$ |
|
% |
|
||||||
Chamberlain: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating income (GAAP) |
|
$ |
47,895 |
|
$ |
47,493 |
|
$ |
402 |
|
0.8 |
% |
|
$ |
107,326 |
|
$ |
117,628 |
|
$ |
(10,302) |
|
(8.8) |
% |
Depreciation |
|
|
6,027 |
|
|
5,350 |
|
|
677 |
|
|
|
|
|
17,108 |
|
|
16,184 |
|
|
924 |
|
|
|
Amortization of cloud computing implementation assets |
|
|
2,073 |
|
|
786 |
|
|
1,287 |
|
|
|
|
|
5,620 |
|
|
2,253 |
|
|
3,367 |
|
|
|
Stock-based compensation |
|
|
2,465 |
|
|
3,178 |
|
|
(713) |
|
|
|
|
|
8,709 |
|
|
10,290 |
|
|
(1,581) |
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
58,460 |
|
$ |
56,807 |
|
$ |
1,653 |
|
2.9 |
% |
|
$ |
138,763 |
|
$ |
146,355 |
|
$ |
(7,592) |
|
(5.2) |
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
29.7 |
% |
|
29.5 |
% |
|
|
|
|
|
|
|
24.8 |
% |
|
27.0 |
% |
|
|
|
|
|
Walden: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating income (GAAP) |
|
$ |
42,376 |
|
$ |
47,999 |
|
$ |
(5,623) |
|
(11.7) |
% |
|
$ |
176,910 |
|
$ |
136,794 |
|
$ |
40,116 |
|
29.3 |
% |
Depreciation |
|
|
2,075 |
|
|
1,951 |
|
|
124 |
|
|
|
|
|
6,089 |
|
|
5,428 |
|
|
661 |
|
|
|
Amortization of cloud computing implementation assets |
|
|
1,918 |
|
|
763 |
|
|
1,155 |
|
|
|
|
|
5,023 |
|
|
2,242 |
|
|
2,781 |
|
|
|
Stock-based compensation |
|
|
3,374 |
|
|
3,288 |
|
|
86 |
|
|
|
|
|
10,264 |
|
|
9,354 |
|
|
910 |
|
|
|
Adjusted EBITDA (non-GAAP) (1) |
|
$ |
49,743 |
|
$ |
54,001 |
|
$ |
(4,258) |
|
(7.9) |
% |
|
$ |
198,286 |
|
$ |
153,818 |
|
$ |
44,468 |
|
28.9 |
% |
Adjusted EBITDA margin (non-GAAP) (1) |
|
|
26.7 |
% |
|
30.3 |
% |
|
|
|
|
|
|
|
33.4 |
% |
|
30.1 |
% |
|
|
|
|
|
Medical and Veterinary: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating income (GAAP) |
|
$ |
21,502 |
|
$ |
17,921 |
|
$ |
3,581 |
|
20.0 |
% |
|
$ |
63,309 |
|
$ |
54,170 |
|
$ |
9,139 |
|
16.9 |
% |
Depreciation |
|
|
3,109 |
|
|
2,785 |
|
|
324 |
|
|
|
|
|
8,936 |
|
|
8,098 |
|
|
838 |
|
|
|
Amortization of cloud computing implementation assets |
|
|
720 |
|
|
304 |
|
|
416 |
|
|
|
|
|
1,836 |
|
|
902 |
|
|
934 |
|
|
|
Stock-based compensation |
|
|
2,129 |
|
|
1,848 |
|
|
281 |
|
|
|
|
|
6,221 |
|
|
5,613 |
|
|
608 |
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
27,460 |
|
$ |
22,858 |
|
$ |
4,602 |
|
20.1 |
% |
|
$ |
80,302 |
|
$ |
68,783 |
|
$ |
11,519 |
|
16.7 |
% |
Adjusted EBITDA margin (non-GAAP) |
|
|
26.5 |
% |
|
24.0 |
% |
|
|
|
|
|
|
|
26.9 |
% |
|
24.7 |
% |
|
|
|
|
|
Home Office: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating loss |
|
$ |
(9,525) |
|
$ |
(8,047) |
|
$ |
(1,478) |
|
(18.4) |
% |
|
$ |
(28,937) |
|
$ |
(25,930) |
|
$ |
(3,007) |
|
(11.6) |
% |
Depreciation |
|
|
166 |
|
|
188 |
|
|
(22) |
|
|
|
|
|
494 |
|
|
557 |
|
|
(63) |
|
|
|
Stock-based compensation |
|
|
1,603 |
|
|
1,949 |
|
|
(346) |
|
|
|
|
|
5,909 |
|
|
5,924 |
|
|
(15) |
|
|
|
Adjusted EBITDA |
|
$ |
(7,756) |
|
$ |
(5,910) |
|
$ |
(1,846) |
|
(31.2) |
% |
|
$ |
(22,534) |
|
$ |
(19,449) |
|
$ |
(3,085) |
|
(15.9) |
% |
Covista: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (GAAP) |
|
$ |
41,637 |
|
$ |
60,832 |
|
$ |
(19,195) |
|
(31.6) |
% |
|
$ |
179,845 |
|
$ |
182,853 |
|
$ |
(3,008) |
|
(1.6) |
% |
Loss (income) from discontinued operations |
|
|
16,345 |
|
|
(38) |
|
|
16,383 |
|
|
|
|
|
15,370 |
|
|
(4,638) |
|
|
20,008 |
|
|
|
Interest expense |
|
|
13,629 |
|
|
13,074 |
|
|
555 |
|
|
|
|
|
35,636 |
|
|
41,465 |
|
|
(5,829) |
|
|
|
Other income, net |
|
|
(232) |
|
|
(1,898) |
|
|
1,666 |
|
|
|
|
|
(4,422) |
|
|
(6,779) |
|
|
2,357 |
|
|
|
Provision for income taxes |
|
|
19,963 |
|
|
18,539 |
|
|
1,424 |
|
|
|
|
|
61,504 |
|
|
51,716 |
|
|
9,788 |
|
|
|
Depreciation and amortization |
|
|
18,893 |
|
|
14,932 |
|
|
3,961 |
|
|
|
|
|
53,521 |
|
|
44,079 |
|
|
9,442 |
|
|
|
Stock-based compensation |
|
|
9,571 |
|
|
10,263 |
|
|
(692) |
|
|
|
|
|
31,103 |
|
|
31,181 |
|
|
(78) |
|
|
|
Restructuring expense |
|
|
863 |
|
|
510 |
|
|
353 |
|
|
|
|
|
5,228 |
|
|
2,926 |
|
|
2,302 |
|
|
|
Litigation reserve |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
(5,550) |
|
|
5,550 |
|
|
|
Asset impairments |
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
|
|
— |
|
|
6,442 |
|
|
(6,442) |
|
|
|
Strategic advisory costs |
|
|
7,238 |
|
|
5,100 |
|
|
2,138 |
|
|
|
|
|
17,032 |
|
|
5,100 |
|
|
11,932 |
|
|
|
Debt modification costs |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
— |
|
|
712 |
|
|
(712) |
|
|
|
Adjusted EBITDA (non-GAAP) (1) |
|
$ |
127,907 |
|
$ |
127,756 |
|
$ |
151 |
|
0.1 |
% |
|
$ |
394,817 |
|
$ |
349,507 |
|
$ |
45,310 |
|
13.0 |
% |
Adjusted EBITDA margin (non-GAAP) (1) |
|
|
26.3 |
% |
|
27.4 |
% |
|
|
|
|
|
|
|
27.2 |
% |
|
26.3 |
% |
|
|
|
|
|
| (1) | Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026. Including the $18.0 million revenue timing impact in the third quarter of fiscal year 2026, Walden adjusted EBITDA would have increased 25.5%, or $13.8 million, to $67.8 million and Walden adjusted EBITDA margin would have been 33.1%. Similarly, consolidated adjusted EBITDA would have increased 14.2%, or $18.2 million, to $145.9 million and consolidated adjusted EBITDA margin would have been 28.9%. |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in Covista’s market risk exposure during the first nine months of fiscal year 2026 from those set forth in Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” contained in our 2025 Form 10-K.
43
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Based on an evaluation of our disclosure controls and procedures (as such term is defined in Exchange Act Rule 13a-15(e)) that was conducted under the supervision and with the participation of Covista’s management, including our Chief Executive Officer and Chief Financial Officer, our Chief Executive Officer and Chief Financial Officer concluded that Covista’s disclosure controls and procedures were effective as of March 31, 2026.
Changes in Internal Control over Financial Reporting
There were no changes during the third quarter of fiscal year 2026 in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Part II. Other Information
Item 1. Legal Proceedings
For information regarding legal proceedings, see Note 17 “Commitments and Contingencies” to the Consolidated Financial Statements included in Item 1. “Financial Statements.”
Item 1A. Risk Factors
There have been no material changes to Covista’s risk factors from those set forth since Item 1A. “Risk Factors” contained in our 2025 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
The table below reflects shares of common stock we repurchased during the third quarter of the fiscal year ended June 30, 2026.
Period |
|
Total Number of Shares Purchased |
|
Average Price Paid per Share |
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) |
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1) |
||
January 1, 2026 - January 31, 2026 |
|
191,280 |
|
$ |
112.91 |
|
191,280 |
|
$ |
705,905,043 |
February 1, 2026 - February 28, 2026 |
|
401,346 |
|
$ |
98.66 |
|
401,346 |
|
$ |
666,309,901 |
March 1, 2026 - March 31, 2026 |
|
44,912 |
|
$ |
100.16 |
|
44,912 |
|
$ |
661,811,630 |
Total |
|
637,538 |
|
$ |
103.04 |
|
637,538 |
|
|
|
(1) |
See Note 14 “Share Repurchases” to the Consolidated Financial Statements for additional information on our share repurchase programs. |
44
Other Purchases of Equity Securities
Period |
|
Total Number of Shares Purchased (1) |
|
Average Price Paid per Share |
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
|
January 1, 2026 - January 31, 2026 |
|
272 |
|
$ |
116.23 |
|
NA |
|
NA |
February 1, 2026 - February 28, 2026 |
|
604 |
|
$ |
95.52 |
|
NA |
|
NA |
March 1, 2026 - March 31, 2026 |
|
— |
|
$ |
— |
|
NA |
|
NA |
Total |
|
876 |
|
$ |
101.95 |
|
NA |
|
NA |
(1) |
Represents shares purchased by Covista for payment of employee withholding taxes on stock awards vesting pursuant to the terms of Covista’s stock incentive plans. |
Item 5. Other Information
On March 9, 2026, Mr. Maurice Herrera, Covista’s former Senior Vice President and Chief Marketing Officer, adopted a 10b5-1 Plan. Mr. Herrera’s 10b5-1 Plan is intended to satisfy the affirmative defense of Rule 10b5-1(c). Trades under Mr. Herrera’s 10b5-1 Plan are subject to the required “cooling-off” period with the estimated first sale date under Mr. Herrera’s 10b5-1 Plan to occur not before June 8, 2026. Mr. Herrera’s 10b5-1 Plan expires on December 31, 2026. The 10b5-1 Plan governs Mr. Herrera’s sale of 8,753 shares of Covista common stock. Transactions under the 10b5-1 Plan will be disclosed publicly through Form 144.
Item 6. Exhibits
3.1 |
|
|
3.2 |
|
|
10.1 |
|
|
31.1* |
|
|
31.2* |
|
|
32.1* |
|
|
101.INS |
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* Filed or furnished herewith.
45
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Covista Inc. |
|
|
|
|
Date: May 7, 2026 |
By: |
/s/ Robert J. Phelan |
|
|
Robert J. Phelan |
|
|
Senior Vice President and Chief Financial Officer |
|
|
(Principal Financial Officer) |
46
Exhibit 10.1
Execution Version
CREDIT AGREEMENT
Dated as of August 12, 2021
(as amended by Amendment No. 1 to Credit Agreement, dated as of June 27, 2023, Amendment No. 2 to Credit Agreement, dated as of January 26, 2024, Amendment No. 3 to Credit Agreement, dated as of August 21, 2024, Amendment No. 4 to Credit Agreement and Incremental Assumption Agreement, dated as of August 6, 2025 and Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement, dated as of March 2, 2026),
Among
COVISTA INC. (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION INC.),
as Borrower,
THE LENDERS PARTY HERETO,
MORGAN STANLEY SENIOR FUNDING, INC.,
as Administrative Agent,
MORGAN STANLEY SENIOR FUNDING, INC.,
TRUIST SECURITIES, INC.,
MUFG BANK, LTD.,
and
U.S. BANK NATIONAL ASSOCIATION,
as Joint Lead Arrangers and Joint Bookrunners,
KEYBANK NATIONAL ASSOCIATION,
ASSOCIATED BANK, N.A.,
BARCLAYS BANK PLC,
FIFTH THIRD BANK, NATIONAL ASSOCIATION,
and
THE NORTHERN TRUST COMPANY,
as Syndication Agents,
PNC BANK, NATIONAL ASSOCIATION
and
VALLEY NATIONAL BANK,
as Documentation Agents
and
MORGAN STANLEY SENIOR FUNDING, INC.,
as Collateral Agent
iv
Exhibits and Schedules
|
|
|
|
|
|
|
|
Exhibit A |
|
Form of Assignment and Acceptance |
|
Exhibit B |
|
Form of Administrative Questionnaire |
|
Exhibit C |
|
Form of Solvency Certificate |
|
Exhibit D-1 |
|
Form of Borrowing Request |
|
Exhibit D-2 |
|
Form of Swingline Borrowing Request |
|
Exhibit E |
|
Form of Interest Election Request |
|
Exhibit F |
|
Form of Mortgage |
|
Exhibit G |
|
Form of Permitted Loan Purchase Assignment and Acceptance |
|
Exhibit H |
|
Form of First Lien/Second Lien Intercreditor Agreement |
|
Exhibit I |
|
Form of U.S. Tax Compliance Certificate |
|
Exhibit J |
|
Form of Intercompany Subordination Terms |
|
|
|
||
Schedule 1.01(A) |
|
Certain Excluded Equity Interests |
|
Schedule 1.01(B) |
|
Mortgaged Properties |
|
Schedule 1.01(C) |
|
Immaterial Subsidiaries |
|
Schedule 1.01(E) |
|
Closing Date Unrestricted Subsidiaries |
|
Schedule 1.01 (F) |
|
Deemed EBITDA |
|
Schedule 2.01 |
|
Commitments |
|
Schedule 3.01 |
|
Organization and Good Standing |
|
Schedule 3.04 |
|
Governmental Approvals |
|
Schedule 3.05 |
|
Financial Statements |
|
Schedule 3.08(a) |
|
Subsidiaries |
|
Schedule 3.08(b) |
|
Subscriptions |
|
Schedule 3.13 |
|
Taxes |
|
Schedule 3.16 |
|
Environmental Matters |
|
Schedule 3.21 |
|
Insurance |
|
Schedule 3.23 |
|
Intellectual Property |
|
Schedule 3.26 |
|
Certain Regulatory Matters |
|
Schedule 5.10 |
|
Post-Closing Items |
|
Schedule 6.01 |
|
Indebtedness |
|
Schedule 6.02(a) |
|
Liens |
|
Schedule 6.04 |
|
Investments |
|
Schedule 6.07 |
|
Transactions with Affiliates |
|
Schedule 10.01 |
|
Notice Information |
|
CREDIT AGREEMENT dated as of August 12, 2021 (as amended by that certain Amendment No. 1 to Credit Agreement, dated as of June 27, 2023, that certain Amendment No. 2 to Credit Agreement, dated as of January 26, 2024, that certain Amendment No. 3 to Credit Agreement, dated as of August 21, 2024, that certain Amendment No. 4 to Credit Agreement and Incremental Assumption Agreement, dated as of August 6, 2025, and Amendment No. 5 to Credit Agreement and Incremental Assumption Agreement, dated as of March 2, 2026, this “Agreement”), among COVISTA INC. (FORMERLY KNOWN AS ADTALEM GLOBAL EDUCATION INC.), a Delaware corporation (the “Borrower”), the LENDERS party hereto from time to time, and MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent (together with any successor entity in such capacity, the “Administrative Agent”) for the Lenders and as Collateral Agent (as defined herein).
WHEREAS, the Borrower has entered into the Membership Interest Purchase Agreement dated as of September 11, 2020 (as amended from time to time prior to the date hereof, the “MIPA”) with Laureate Education, Inc., a Delaware public benefit corporation (the “Seller”), pursuant to which the Borrower will directly or indirectly acquire all of the issued and outstanding limited liability company interests of Walden e-Learning, LLC a Delaware limited liability company (the “Walden Target” and such acquisition, the “Walden Acquisition”); and
WHEREAS, in connection with the consummation of the Walden Acquisition, the Borrower has requested the Lenders to extend credit in the form of (a) Term B Loans on the Closing Date in an aggregate principal amount of $850,000,000 and (b) Revolving Facility Loans and Letters of Credit at any time and from time to time prior to the Revolving Facility Maturity Date, in an aggregate principal amount at any time outstanding not in excess of $400,000,000.
NOW, THEREFORE, the Lenders and the Issuing Banks are willing to extend such credit to the Borrower on the terms and subject to the conditions set forth herein. Accordingly, the parties hereto agree as follows:
2
3
4
5
“Applicable Law” shall mean, as to any person, all applicable Laws binding upon such person or to which such a person is subject.
6
7
8
9
10
11
12
13
14
15
16
17
“Connection Income Taxes” shall mean Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.
18
19
20
21
22
23
24
25
“Domestic Subsidiary” shall mean any Subsidiary that is not a Foreign Subsidiary.
“EBITDA” shall mean, with respect to the Borrower and its Subsidiaries on a consolidated basis for any period, the Consolidated Net Income of the Borrower and its Subsidiaries for such period plus (a) the sum of (in each case without duplication and to the extent the respective amounts described in subclauses (i) through (xv) of this clause (a) reduced such Consolidated Net Income (and were not excluded therefrom) for the respective period for which EBITDA is being determined):
26
27
28
29
30
31
32
33
34
35
“Existing Indebtedness Refinancing” shall mean (a) (i) the prepayment of all of the existing and outstanding indebtedness under that certain Credit Agreement, dated as of April 13, 2018 (as amended from time to time, the “Existing Borrower Credit Agreement”), among the Borrower, certain of the Borrower’s subsidiaries identified therein, the lenders party thereto and Bank of America, N.A., as administrative agent, (ii) the termination of the Existing Borrower Credit Agreement and any related agreements under which such indebtedness was issued or incurred and (iii) termination and release of all related security and guarantees (if any) and (b) (i) the termination and release of all security and guarantees (if any) with respect to the Walden Target and its subsidiaries under the Third Amended and Restated Credit Agreement, dated as of October 7, 2019 among the Seller, as borrower, the lending institutions from time to time party thereto and Citibank, N.A., as administrative agent and collateral agent and (ii) terminate and release all security and guarantees (if any) with respect to the Walden Target and its subsidiaries under the Indenture dated as of April 21, 2017 among the Seller, as issuer, the subsidiary guarantors party thereto and Wells Fargo Bank, National Association, as trustee.
36
37
38
39
40
“Historical Walden Financial Statements” with respect to the Walden Target and its Subsidiaries, (i) the audited carveout consolidated statement of operations, consolidated balance sheet, consolidated statement of cash flows and consolidated statement of changes in member’s equity for the Walden Target and its Subsidiaries as of and for the fiscal years ended December 31, 2018 and 2019 and thereafter for the most recently completed fiscal years ended at least 60 days prior to the Closing Date, including the notes and schedules thereto, accompanied by the reports thereon of the Walden Target’s and its Subsidiaries’ independent auditors for the years then ended; (ii) the unaudited carveout consolidated statement of operations, consolidated balance sheet, consolidated statement of cash flows and consolidated statement of changes in member’s equity for the Walden Target and its Subsidiaries as of and for the six months ended June 30, 2020, and the comparable prior period, including the notes and schedules thereto, accompanied by the reports thereon of the Walden Target’s and its Subsidiaries’ independent auditors; and (iii) the unaudited carveout consolidated statement of operations, consolidated balance sheet, consolidated statement of cash flows and consolidated statement of changes in member’s equity for the Walden Target and its Subsidiaries as of and for each subsequent interim fiscal quarter ended since the last audited financial statements and at least 40 days prior to the Closing Date (other than the fourth fiscal quarter), and the comparable prior period, including the notes and schedules thereto, accompanied by the reports thereon of the Walden Target’s and its Subsidiaries’ independent auditors.
41
42
provided, that for purposes of determining the Incremental Amount, (A) if the Borrower incurs Indebtedness under an Incremental Facility or Incremental Equivalent Debt using the Fixed Incremental Amount on the same date that it incurs Indebtedness using the Ratio Incremental Amount, the Net First Lien Leverage Ratio or other applicable ratio will be calculated without regard to any incurrence of Indebtedness under the Fixed Incremental Amount, (B) if the applicable incurrence test is satisfied on a Pro Forma Basis after giving effect to any Incremental Facility or Incremental Equivalent Debt in lieu thereof, such Incremental Facility or Incremental Equivalent Debt, as applicable, may be incurred under the Ratio Incremental Amount regardless of whether there is capacity under the Fixed Incremental Amount and (C) in the event that any Incremental Facility or Incremental Equivalent Debt (or a portion thereof) incurred under a Fixed Incremental Amount subsequently meets the criteria of Indebtedness permitted to be incurred under the Ratio Incremental Amount, the Borrower, in its sole discretion, at such time may divide and classify any such Indebtedness as Indebtedness incurred under the Ratio Incremental Amount, and the applicable Fixed Incremental Amount shall be deemed to be increased by the amount so reclassified.
43
44
45
46
47
48
49
“Marketing Period” shall have the meaning assigned to such term in Section 4.01(o).
50
51
52
53
54
55
56
57
58
Net First Lien Leverage Ratio |
Applicable |
Applicable Margin for Term SOFR 2025 Refinancing Revolving Facility Loans, |
|---|---|---|
Greater than or equal to 2.23:1.00 |
2.00% |
3.00% |
Less than 2.23:1.00 but greater than or equal to 1.73:1.00 |
1.75% |
2.75% |
Less than 1.73:1.00 but greater than or equal to 1.23:1.00 |
1.50% |
2.50% |
Less than 1:23:1.00 |
1.25% |
2.25% |
For the purposes of the Pricing Grid, changes in the Applicable Margin resulting from changes in the Net First Lien Leverage Ratio shall become effective on the date (the “Adjustment Date”) that is three Business Days after the date on which the relevant financial statements are delivered to the Lenders pursuant to Section 5.04 for each fiscal quarter beginning with the first full fiscal quarter of the Borrower ended after the Closing Date, and shall remain in effect until the next change to be effected pursuant to this paragraph. If any financial statements referred to above are not delivered within the time periods specified in Section 5.04, then, at the option of the Administrative Agent or the Required Lenders, until the date that is three Business Days after the date on which such financial statements are delivered, the pricing level that is one pricing level higher than the pricing level theretofore in effect shall apply as of the first Business Day after the date on which such financial statements were to have been delivered but were not delivered. Each determination of the Net First Lien Leverage Ratio pursuant to the Pricing Grid shall be made in a manner consistent with the determination thereof pursuant to Section 6.11.
59
60
“Pro Forma Financial Statements” shall mean, (i) a pro forma consolidated statements of income of the Borrower for the most recently completed fiscal year ended at least 60 days prior to the Closing Date and a pro forma consolidated balance sheet and related pro forma consolidated statements of income for the interim period ending on the last day of the most recent fiscal quarter ended since the last audited financial statements and ending at least 40 days before the Closing Date and (ii) a pro forma consolidated balance sheet and related consolidated statement of income as of and for the 12-month period ending on the last day of the most recently completed four-fiscal quarter period for which historical financial statements of the Borrower are provided pursuant to Section 4.01(f), prepared after giving pro forma effect to each element of the Transactions as if the Transactions had occurred on the last day of such interim period (in the case of such balance sheet) or at the beginning of such period (in the case of such other financial statements).
61
62
63
64
65
66
67
68
69
70
“Specified Acquisition Agreement Representations” shall mean the representations made by the Seller, the Walden Target, its Subsidiaries or its business in the MIPA as are material to the interests of the Lenders, but only to the extent that the Borrower or its affiliates have the right to terminate its obligations pursuant to Section 7.01(c) of the MIPA or otherwise decline to consummate the Acquisition pursuant to Section 6.02(a) of the MIPA as a result of a breach of any such Specified Acquisition Agreement Representations (after giving effect to any applicable notice and cure provisions) or any such Specified Acquisition Agreement Representations not being accurate.
“Specified Indebtedness” means Indebtedness incurred under (i) Section 6.01(h), (ii) Section 6.01(i), (iii) Section 6.01(j), (iv) Section 6.01(k), (v) Section 6.01(r), (vi) Sections 6.01(t), (w), (z), (aa) or (bb) (in each case incurred by a Subsidiary of the Borrower that is not a Subsidiary Loan Party), (vii) Section 6.01(gg) or (viii) any other provision of this Agreement that constitutes Permitted Earlier Maturity Debt.
“Specified Representations” shall mean those representations and warranties made by the Borrower in Sections 3.01(a) (with respect to the Loan Parties only), 3.01(b) (with respect to the Loan Parties only), 3.01(d) (with respect to the Loan Parties only), 3.02(a), 3.02(b)(i)(B) 3.03, 3.10, 3.11, 3.17 (as it relates to the creation, validity and perfection of the security interests in the Collateral), 3.19, 3.25(b) and 3.26.
“Specified Transaction” shall mean any Investment that results in a person becoming a Subsidiary, any designation of a subsidiary as a Subsidiary or an Unrestricted Subsidiary, any Permitted Business Acquisition, any Disposition that results in a Subsidiary ceasing to be a subsidiary of the Borrower, any Investment constituting an acquisition of assets constituting a business unit, line of business or division of another person or any Disposition of a business unit, line of business or division of the Borrower or a Subsidiary, in each case, whether by merger, consolidation, amalgamation or otherwise, or any incurrence or repayment of Indebtedness (other than Indebtedness incurred or repaid under any revolving credit facility in the ordinary course of business for working capital purposes), Restricted Payment, Subsidiary designation, Incremental Term Facility, Incremental Revolving Facility Commitment or other event that by the terms of this Agreement requires EBITDA or a financial ratio or test to be calculated on a “Pro Forma Basis.”
71
72
73
74
75
76
77
“Walden Acquisition” shall have the meaning assigned to such term in the first recital hereto.
78
For purposes of determining compliance at any time with Sections 6.01, 6.02, 6.03, 6.04, 6.05, 6.06 and 6.07, in the event that any Indebtedness, Lien, payment with respect to Junior Financing restricted by Section 6.06(b), Restricted Payment, contractual restriction, Investment, Disposition or Affiliate transaction, as applicable, meets the criteria of more than one of the categories of transactions or items permitted pursuant to any clause of such Sections 6.01, 6.02, 6.03, 6.04, 6.05, 6.06 and 6.07, the Borrower, in its sole discretion, from time to time, may classify or reclassify such transaction or item (or portion thereof) and will only be required to include the amount and type of such transaction (or portion thereof) in any one category. For purposes of determining the permissibility of any action, change, transaction or event that by the terms of the Loan Documents requires a calculation of any financial ratio or test (including the Net First Lien Leverage Ratio, the Total Net Leverage Ratio or the Net Secured Leverage Ratio), such financial ratio or test shall, except as expressly permitted under this Agreement, be calculated at the time such action is taken, such change is made, such transaction is consummated or such event occurs, as the case may be, and no Default or Event of Default shall be deemed to have occurred solely as a result of a change in such financial ratio or test occurring after the time such action is taken, such change is made, such transaction is consummated or such event occurs, as the case may be.
79
It is understood and agreed that any Indebtedness, Lien, Restricted Payment, payment with respect to Junior Financing restricted by Section 6.09(b), Investment, Disposition or Affiliate transaction need not be permitted solely by reference to one category of permitted Indebtedness, Liens, Restricted Payments, payments with respect to Junior Financing, Investments, Dispositions or Affiliate transactions under Sections 6.01, 6.02, 6.04, 6.05, 6.06, 6.09(b) or 6.07, respectively, but may instead be permitted in part under any combination thereof (it being understood that compliance with each such section is separately required).
80
81
of the immediately preceding sentence, any such ratio, basket or compliance with any other provision hereunder shall be calculated on a Pro Forma Basis assuming such Limited Condition Transaction and other transactions in connection therewith (including any incurrence or issuance of Indebtedness or Disqualified Stock, and the use of proceeds thereof) had been consummated on the LCT Test Date; provided that for purposes of any Restricted Payment or payment of a Junior Financing, such ratio, basket or compliance with any other provision hereunder shall also be tested as if such Limited Condition Transaction and other transactions in connection therewith (including any incurrence or issuance of Indebtedness or Disqualified Stock, and the use of proceeds thereof) had not been consummated.
On and after the date Pro Forma Basis is to be given to a Limited Condition Transaction and on which the Borrower or any Subsidiary is incurring or deemed to be incurring Indebtedness, which Limited Condition Transaction has yet to be consummated but for which a definitive agreement governing such Limited Condition Transaction has been executed and remains in effect, any ratio based conditions and baskets (including baskets that are determined on the basis of EBITDA) shall be required to be satisfied assuming both that such Limited Condition Transaction has been consummated and the related Indebtedness incurred and that such Limited Condition Transaction has not been consummated and the related Indebtedness has not been incurred, in each case until such Limited Condition Transaction is consummated or such definitive agreement is terminated.
82
83
84
If no election as to the Type of Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period is specified with respect to any requested Term SOFR Borrowing, Eurocurrency Borrowing or Alternate Currency Borrowing, then the Borrower shall be deemed to have selected an Interest Period of one month’s duration.
85
Promptly following receipt of a Borrowing Request in accordance with this Section 2.03, the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender’s Loan to be made as part of the requested Borrowing.
86
87
In the event of any inconsistency between the terms and conditions of this Agreement and the terms and conditions of any form of letter of credit application or other agreement submitted by the Borrower to, or entered into by the Borrower with, an Issuing Bank relating to any Letter of Credit, the terms and conditions of this Agreement shall control.
88
89
90
91
92
93
94
If any such Interest Election Request requests a Term SOFR Borrowing, Eurocurrency Borrowing or Alternate Currency Borrowing but does not specify an Interest Period, then the Borrower shall be deemed to have selected an Interest Period of one month’s duration. If less than all the outstanding principal amount of any Borrowing shall be converted or continued, then each resulting Borrowing shall be in an integral multiple of the Borrowing Multiple and not less than the Borrowing Minimum and satisfy the limitations specified in Sections 2.02(c) regarding the maximum number of Borrowings of the relevant Type.
95
2 Effective Date will terminate. On the Amendment No. 3 Effective Date (after giving effect to the funding of the 2024 Second Repricing Term Loans to be made on such date), the 2024 Second Repricing Term Loan Commitments of the 2024 Second Repricing Term Lender as of the Amendment No. 3 Effective Date will terminate. On the Amendment No. 5 Effective Date (after giving effect to the funding of the 2026 Term Loans to be made on such date), the 2026 Incremental Term Loan Commitments and the 2026 Refinancing Term Loan Commitments of the 2026 Term Lenders as of the Amendment No. 5 Effective Date will terminate.
96
97
98
99
100
101
102
103
104
(i)(A) a Benchmark Transition Event and (B) a Benchmark Replacement Date with respect thereto have occurred prior to the Reference Time in connection with any setting of the then-current Benchmark, then:
(x)if a Benchmark Replacement is determined in accordance with clause (1) of the definition of “Benchmark Replacement” with respect to Dollars for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes under this Agreement and under any other Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without requiring any amendment to, or requiring any further action by or consent of any other party to, this Agreement or any other Loan Document, and
(y)if a Benchmark Replacement is determined in accordance with clause (2) of the definition of “Benchmark Replacement” with respect to any Alternate Currency for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes under this Agreement and under any other Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without requiring any amendment to, or requiring any further action by or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders of each Class.
105
106
107
108
109
110
111
Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.
112
113
114
115
116
117
118
Each party hereto hereby agrees that, upon the effectiveness of any Incremental Assumption Agreement, this Agreement shall be amended to the extent (but only to the extent) necessary to reflect the existence and terms of the Incremental Term Loan Commitments and/or Incremental Revolving Facility Commitments evidenced thereby as provided for in Section 10.08(e). Any amendment to this Agreement or any other Loan Document that is necessary to effect the provisions of this Section 2.21 and any such collateral and other documentation shall be deemed “Loan Documents” hereunder and may be memorialized in writing by the Administrative Agent with the Borrower’s consent (not to be unreasonably withheld) and furnished to the other parties hereto.
119
120
121
122
123
124
125
126
127
128
129
On the date of each Credit Event, the Borrower represents and warrants to each of the Lenders that:
130
This Agreement has been duly executed and delivered by the Borrower and constitutes, and each other Loan Document when executed and delivered by each Loan Party that is party thereto will constitute, a legal, valid and binding obligation of such Loan Party enforceable against each such Loan Party in accordance with its terms, subject to (i) the effects of bankruptcy, insolvency, moratorium, reorganization, fraudulent conveyance or other similar laws affecting creditors’ rights generally, (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law), (iii) implied covenants of good faith and fair dealing and (iv) any foreign laws, rules and regulations as they relate to pledges of Equity Interests in Foreign Subsidiaries that are not Loan Parties.
131
132
133
134
135
136
137
The obligations of (a) the Lenders (including the Swingline Lender) to make Loans and (b) any Issuing Bank to issue, amend, extend or renew Letters of Credit or increase the stated amounts of Letters of Credit hereunder (each, a “Credit Event”) are subject to the satisfaction (or waiver in accordance with Section 10.08) of the following conditions:
138
139
140
Notwithstanding anything herein to the contrary, it is understood that, other than with respect to any Collateral perfected by (A) the filing of a UCC financing statement, (B) the filing of a security agreement with the U.S. Patent and Trademark Office or the U.S. Copyright Office or (C) taking delivery and possession of a stock certificate, to the extent any Lien on any Collateral is not or cannot be provided or perfected on the Closing Date after the Borrower’s use of commercially reasonable efforts to do so or without undue burden or expense, the delivery and/or provision of and/or perfection of a Lien on such Collateral shall not constitute a condition precedent to the availability of the Facilities on the Closing Date, but instead shall be required to be delivered after the Closing Date in accordance with Schedule 5.10.
For purposes of determining compliance with the conditions specified in this Section 4.01, each Lender shall be deemed to have consented to, approved or accepted or to be satisfied with each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to the Lenders unless an officer of the Administrative Agent responsible for the transactions contemplated by the Loan Documents shall have received notice from such Lender prior to the Closing Date specifying its objection thereto and, in the case of a Borrowing, such Lender shall not have made available to the Administrative Agent such Lender’s ratable portion of the initial Borrowing.
141
Each Borrowing and each other Credit Event that occurs after the Closing Date shall be deemed to constitute a representation and warranty by the Borrower on the date of such Borrowing, issuance, amendment, extension or renewal as applicable, as to the matters specified in paragraphs (b) and (c) of this Section 4.02; provided, however, the application of clauses (b) and (c) hereto to any Incremental Loan shall be as provided in the applicable Incremental Assumption Agreement, and, to the extent made in connection with any Limited Condition Transaction shall, at the Borrower’s option, be subject to Section 1.07.
The Borrower covenants and agrees with each Lender that, until the Termination Date, unless the Required Lenders shall otherwise consent in writing, the Borrower will, and will cause each of its Subsidiaries to:
142
143
144
The Borrower hereby acknowledges and agrees that all financial statements and certificates furnished pursuant to paragraphs (a), (b) and (d) above are hereby deemed to be Borrower Materials suitable for distribution, and to be made available, to Public Lenders as contemplated by Section 10.17 and may be treated by the Administrative Agent and the Lenders as if the same had been marked “PUBLIC” in accordance with such paragraph (unless the Borrower otherwise notifies the Administrative Agent in writing on or prior to delivery thereof).
145
146
147
148
149
All representations and warranties contained in this Agreement and the other Loan Documents shall be deemed modified to the extent necessary to effect the foregoing (and to permit the taking of the actions contemplated by this Section 5.13 within the time periods specified in Schedule 5.13, rather than as elsewhere provided in the Loan Documents); provided that (x) to the extent any representation and warranty would not be true because the foregoing actions were not taken on the Closing Date, the respective representation and warranty shall be required to be true and correct in all material respects at the time the respective action is taken (or was required to be taken) in accordance with the foregoing provisions of this Section 5.13 (and Schedule 5.13) and (y) all representations and warranties relating to the assets set forth on Schedule 5.13 pursuant to the Security Documents shall be required to be true in all material respects immediately after the actions required to be taken under this Section 5.13 (and Schedule 5.13) have been taken (or were required to be taken), except to the extent any such representations and warranties expressly relate to an earlier date in which case such representations and warranties shall be true and correct in all material respects as of such earlier date.
The Borrower covenants and agrees with each Lender that, until the Termination Date, unless the Required Lenders (or, in the case of Section 6.11, the Required Revolving Facility Lenders voting as a single Class) shall otherwise consent in writing, the Borrower will not, and will not permit any of its Subsidiaries to:
150
151
152
153
154
155
For purposes of determining compliance with this Section 6.01, the amount of any Indebtedness denominated in any currency other than Dollars shall be calculated based on customary currency exchange rates in effect, in the case of such Indebtedness incurred (in respect of term Indebtedness) or committed (in respect of revolving Indebtedness) on or prior to the Closing Date, on the Closing Date and, in the case of such Indebtedness incurred (in respect of term Indebtedness) or committed (in respect of revolving Indebtedness) after the Closing Date, on the date on which such Indebtedness was incurred (in respect of term Indebtedness) or committed (in respect of revolving Indebtedness); provided that if such Indebtedness is incurred to refinance other Indebtedness denominated in a currency other than Dollars (or in a different currency from the Indebtedness being refinanced), and such refinancing would cause the applicable Dollar-denominated restriction to be exceeded if calculated at the relevant currency exchange rate in effect on the date of such refinancing, such Dollar-denominated restriction shall be deemed not to have been exceeded so long as the principal amount of such refinancing Indebtedness does not exceed (i) the outstanding or committed principal amount, as applicable, of such Indebtedness being refinanced plus (ii) the aggregate amount of fees, underwriting discounts, premiums (including tender premiums), defeasance costs and other costs and expenses incurred in connection with such refinancing.
Further, for purposes of determining compliance with this Section 6.01, (A) Indebtedness need not be permitted solely by reference to one category of permitted Indebtedness described in Sections 6.01(a) through (hh) but may be permitted in part under any combination thereof and (B) in the event that an item of Indebtedness (or any portion thereof) meets the criteria of one or more of the categories of permitted Indebtedness described in Sections 6.01(a) through (hh), the Borrower shall, in its sole discretion, classify or reclassify, or later divide, classify or reclassify, such item of Indebtedness (or any portion thereof) in any manner that complies with this Section 6.01 and will only be required to include the amount and type of such item of Indebtedness (or any portion thereof) in one of the above clauses and such item of Indebtedness shall be treated as having been incurred or existing pursuant to only one of such clauses; provided that (x) all Indebtedness outstanding on the Closing Date under this Agreement shall at all times be deemed to have been incurred pursuant to clause (b) of this Section 6.01 and (y) all Indebtedness outstanding on the Closing Date under the First Lien Notes shall at all times be deemed to have been incurred pursuant to clause (p) of this Section 6.01. In addition, with respect to any Indebtedness that was permitted to be incurred hereunder on the date of such incurrence, any Increased Amount of such Indebtedness shall also be permitted hereunder after the date of such incurrence.
156
157
158
159
160
161
For purposes of determining compliance with this Section 6.02, (A) a Lien securing an item of Indebtedness need not be permitted solely by reference to one category of Liens permitted by this Agreement described in Sections 6.02(a) through (mm) but may be permitted in part under any combination thereof and (B) in the event that a Lien securing an item of Indebtedness (or any portion thereof) meets the criteria of one or more of the categories of Liens permitted by this Agreement described in Sections 6.02(a) through (mm), the Borrower shall, in its sole discretion, classify or reclassify, or later divide, classify or reclassify, such Lien securing such item of Indebtedness (or any portion thereof) in any manner that complies with this covenant and will only be required to include the amount and type of such Lien or such item of Indebtedness secured by such Lien in one of the above clauses and such Lien securing such item of Indebtedness will be treated as being incurred or existing pursuant to only one of such clauses.
162
In addition, with respect to any Lien securing Indebtedness that was permitted to secure such Indebtedness at the time of the incurrence of such Indebtedness, such Lien shall also be permitted to secure any Increased Amount of such Indebtedness.
With respect to any Indebtedness secured by Liens referred to in the proviso to Section 6.02(hh) or in the proviso to clause (h) in the definition of “Refinancing Notes” that in either case is in the form of U.S. Dollar denominated term loans that rank pari passu in right of payment and security with the Term Loans (other than any such term loans that are incurred after the 12 month anniversary of the Amendment No. 5 Effective Date or that are scheduled to mature on or after the date that is one year after the 2026 Term Loan Maturity Date), if the All-in Yield in respect of such Pari Term Loans exceeds the All-in Yield in respect of the 2026 Term Loans on the Amendment No. 5 Date by more than 0.50% (such difference, the “Pari Yield Differential”), then the Applicable Margin (or “SOFR floor” as provided in the following proviso) applicable to such 2026 Term Loans on the Closing Date shall be increased such that after giving effect to such increase, the Pari Yield Differential shall not exceed 0.50%; provided that, to the extent any portion of the Pari Yield Differential is attributable to a higher “SOFR floor” being applicable to such Pari Term Loans, such floor shall only be included in the calculation of the Pari Yield Differential to the extent such floor is greater than the Adjusted Term SOFR Rate in effect for an Interest Period of three months’ duration at such time, and, with respect to such excess, the “SOFR floor” applicable to such outstanding 2026 Term Loans shall be increased to an amount not to exceed the “SOFR floor” applicable to such Pari Term Loans prior to any increase in the Applicable Margin applicable to such 2026 Term Loans then outstanding.
163
(i) Purchase or acquire (including pursuant to any merger with a person that is not a Wholly Owned Subsidiary immediately prior to such merger) any Equity Interests, evidences of Indebtedness or other securities of any other person, (ii) make any loans or advances to or Guarantees of the Indebtedness of any other person (other than loans or advances in respect of (A) intercompany current liabilities incurred in connection with the cash management operations of the Borrower and its Subsidiaries and (B) intercompany loans, advances or Indebtedness having a term not exceeding 364 days (inclusive of any roll-overs or extensions of terms) and made in the ordinary course of business or consistent with industry practices), or (iii) purchase or otherwise acquire, in one transaction or a series of related transactions, (x) all or substantially all of the property and assets or business of another person or (y) assets constituting a business unit, line of business or division of such person (each of the foregoing, an “Investment”), except:
164
165
166
167
Any Investment in any person other than the Borrower or a Subsidiary Loan Party that is otherwise permitted by this Section 6.04 may be made through intermediate Investments in Subsidiaries that are not Loan Parties and such intermediate Investments shall be disregarded for purposes of determining the outstanding amount of Investments pursuant to any clause set forth above. The amount of any Investment made other than in the form of cash or Permitted Investments shall be the fair market value thereof (as determined by the Borrower in good faith) valued at the time of the making thereof, and without giving effect to any subsequent write-downs or write-offs thereof.
168
169
170
Notwithstanding anything to the contrary contained in Section 6.05 above, (i) no Disposition of assets under Section 6.05(d) and Section 6.05(g) shall be permitted unless such Disposition is for fair market value (as determined in good faith by the Borrower), or if not for fair market value, the shortfall is permitted as an Investment under Section 6.04, and (ii) no Disposition of assets under Section 6.05(g) shall be permitted unless such Disposition (except to Loan Parties) is for at least 75% cash consideration or consideration consisting of Permitted Investments; provided that the provisions of this clause (ii) shall not apply to any individual transaction or series of related transactions involving assets with a fair market value (as determined in good faith by the Borrower) of less than $40,000,000 or to other transactions involving assets with a fair market value of not more than $60,000,000 in the aggregate for all such transactions during any fiscal year; provided, further, that for purposes of this clause (ii), each of the following shall be deemed to be cash: (a) the amount of any liabilities (as shown on the Borrower’s or such Subsidiary’s most recent balance sheet or in the notes thereto) that are assumed by the transferee of any such assets or are otherwise cancelled in connection with such transaction, (b) any notes or other obligations or other securities or assets received by the Borrower or such Subsidiary from the transferee that are converted by the Borrower or such Subsidiary into cash within 180 days after receipt thereof (to the extent of the cash received) and (c) any Designated Non-Cash Consideration received by the Borrower or any of its Subsidiaries in such Disposition having an aggregate fair market value (as determined in good faith by the Borrower), taken together with all other Designated Non-Cash Consideration received pursuant to this clause (c) that is at that time outstanding, not to exceed the greater of $102,270,000 and 21% of EBITDA as of the end of the fiscal quarter immediately prior to the receipt of such Designated Non-Cash Consideration for which financial statements have been delivered pursuant to Section 5.04(a) or 5.04(b) (with the fair market value of each item of Designated Non-Cash Consideration being measured at the time received and without giving effect to subsequent changes in value).
171
172
173
174
175
176
177
178
Test Periods Ending |
Total Net Leverage Ratio |
|---|---|
December 31, 2021 through December 31, 2023 |
4.00:1.00 |
Thereafter |
3.25:1.00 |
179
180
then, and in every such event (other than an event with respect to the Borrower described in clause (h) or (i) above), and at any time thereafter during the continuance of such event, the Administrative Agent, at the request of the Required Lenders, shall, by notice to the Borrower, take any or all of the following actions, at the same or different times: (i) terminate forthwith the Commitments, (ii) declare the Loans then outstanding to be forthwith due and payable in whole or in part, whereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower accrued hereunder and under any other Loan Document, shall become forthwith due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived by the Borrower, anything contained herein or in any other Loan Document to the contrary notwithstanding and (iii) if the Loans have been declared due and payable pursuant to clause (ii) above, demand Cash Collateral pursuant to Section 2.05(j); and in any event with respect to the Borrower described in clause (h) or (i) above, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower accrued hereunder and under any other Loan Document, shall automatically become due and payable and the Administrative Agent shall be deemed to have made a demand for Cash Collateral to the full extent permitted under Section 2.05(j), without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived by the Borrower, anything contained herein or in any other Loan Document to the contrary notwithstanding.
181
For purposes of clauses (h) and (i) of this Section 8.01, “Material Subsidiary” shall mean any Subsidiary that would not be an Immaterial Subsidiary under clause (a) of the definition thereof.
182
183
No Agent shall be under any obligation to any Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of any Loan Party. No Agent shall have any duties or obligations except those expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, (a) no Agent shall be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing, and (b) no Agent shall, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by such Agent or any of its Affiliates in any capacity. The Agents shall be deemed not to have knowledge of any Default or Event of Default unless and until written notice describing such Default or Event of Default is given to the Administrative Agent by the Borrower, a Lender or Issuing Bank. No Agent shall be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or the creation, perfection or priority of any Lien purported to be created by the Security Documents, (v) the value or the sufficiency of any Collateral, (vi) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent or (vii) compliance by the Borrower or any of its Subsidiaries with the terms hereof relating to Permitted Loan Purchases.
184
Each Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement and the other Loan Documents in accordance with a request of the Required Lenders (or, if so specified by this Agreement, all or other Lenders), and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders and all future holders of the Loans.
185
The Lenders agree to indemnify each Agent and the Revolving Facility Lenders agree to indemnify each Issuing Bank, in each case in its capacity as such (to the extent not reimbursed by the Borrower and without limiting the obligation of the Borrower to do so), in the amount of its pro rata share (based on its aggregate Revolving Facility Credit Exposure and, in the case of the indemnification of each Agent, outstanding Term Loans and unused Commitments hereunder; provided that the aggregate principal amount of Swingline Loans owing to the Swingline Lender and of L/C Disbursements owing to any Issuing Bank shall be considered to be owed to the Revolving Facility Lenders ratably in accordance with their respective Revolving Facility Credit Exposure) (determined at the time such indemnity is sought), from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time (whether before or after the payment of the Loans) be imposed on, incurred by or asserted against such Agent or such Issuing Bank in any way relating to or arising out of the Commitments, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by such Agent or such Issuing Bank under or in connection with any of the foregoing; provided that no Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements that are found by a final and nonappealable decision of a court of competent jurisdiction to have resulted from such Agent’s or such Issuing Bank’s gross negligence or willful misconduct. The failure of any Lender to reimburse any Agent or any Issuing Bank, as the case may be, promptly upon demand for its ratable share of any amount required to be paid by the Lenders to such Agent or such Issuing Bank, as the case may be, as provided herein shall not relieve any other Lender of its obligation hereunder to reimburse such Agent or such Issuing Bank, as the case may be, for its ratable share of such amount, but no Lender shall be responsible for the failure of any other Lender to reimburse such Agent or such Issuing Bank, as the case may be, for such other Lender’s ratable share of such amount. The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.
186
If no successor agent has accepted appointment as Administrative Agent by the date that is 30 days following a retiring Administrative Agent’s notice of resignation, the retiring Administrative Agent’s resignation shall nevertheless thereupon become effective (such date of resignation effectiveness, the “Resignation Effective Date”), and the Lenders shall assume and perform all of the duties of the Administrative Agent and Collateral Agent hereunder until such time, if any, as the Required Lenders appoint a successor agent as provided for above. With effect from the Resignation Effective Date, except for any indemnity payments owed to the retiring Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and Issuing Bank directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above. After any retiring Administrative Agent’s resignation as Administrative Agent, the provisions of this Section 9.09 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Administrative Agent under this Agreement and the other Loan Documents.
The Lenders hereby irrevocably authorize and instruct the Collateral Agent to, without any further consent of any Lender, enter into (or acknowledge and consent to) or amend, renew, extend, supplement, restate, replace, waive or otherwise modify the Intercreditor Agreement, any First Lien/Second Lien Intercreditor Agreement, any Permitted Junior Intercreditor Agreement, any Permitted Pari Passu Intercreditor Agreement or any other intercreditor agreement with the collateral agent or other representatives of the holders of Indebtedness that is permitted to be secured by a Lien on the Collateral that is permitted (including with respect to priority) under this Agreement and to subject the Liens on the Collateral securing the Obligations to the provisions thereof. The Lenders irrevocably agree that (x) the Collateral Agent may rely exclusively on a certificate of a Responsible Officer of the Borrower as to whether any such other Liens are permitted and (y) the Intercreditor Agreement, any First Lien/Second Lien Intercreditor Agreement or any other intercreditor agreement referred to in the foregoing sentence, entered into by the Collateral Agent, shall be binding on the Secured Parties, and each Lender hereby agrees that it will take no actions contrary to the provisions of the Intercreditor Agreement and, if entered into and if applicable, any Permitted Pari Passu Intercreditor Agreement or any Permitted Junior Intercreditor Agreement. The foregoing provisions are intended as an inducement to the holders of the First Lien Notes and any future providers of Indebtedness not prohibited by Section 6.01 hereof to extend credit to the Loan Parties and such persons are intended third-party beneficiaries of such provisions.
187
Furthermore, the Lenders (including in their capacities as potential Cash Management Banks and potential Hedge Banks) hereby authorize the Administrative Agent and the Collateral Agent to release any Lien on any property granted to or held by the Administrative Agent or the Collateral Agent under any Loan Document (i) to the holder of any Lien on such property that is permitted by clauses (c), (i), (j) and (aa) of Section 6.02 or Section 6.02(a) (if the Liens thereunder are of a type that is contemplated by any of the foregoing clauses) in each case to the extent the contract or agreement pursuant to which such Lien is granted prohibits any other Liens on such property or (ii) that is or becomes Excluded Property; and the Administrative Agent and the Collateral Agent shall do so upon request of the Borrower; provided that prior to any such request by the Borrower, upon the reasonable request of the Administrative Agent, the Borrower shall have in each case delivered to the Administrative Agent a certificate of a Responsible Officer of the Borrower certifying (x) that such Lien is permitted under this Agreement, (y) in the case of a request pursuant to clause (i) of this sentence, that the contract or agreement pursuant to which such Lien is granted prohibits any other Lien on such property and (z) in the case of a request pursuant to clause (ii) of this sentence, that (A) such property is or has become Excluded Property and (B) if such property has become Excluded Property as a result of a contractual restriction, such restriction does not violate Section 6.09(c) and, if any restriction referred to in this clause (B) relates to property other than cash, Permitted Investments or joint venture interests, such restriction either existed at the time such property was acquired (and was not created in contemplation of such acquisition) or was permitted by Section 6.09(c)(R).
188
Anything contained in any of the Loan Documents to the contrary notwithstanding, the Borrower, the Administrative Agent, the Collateral Agent and each Secured Party hereby agree that (a) no Secured Party shall have any right individually to realize upon any of the Collateral or to enforce the Guarantee, it being understood and agreed that all powers, rights and remedies hereunder may be exercised solely by the Administrative Agent, on behalf of the Secured Parties in accordance with the terms hereof and all powers, rights and remedies under the Security Documents may be exercised solely by the Collateral Agent, and (b) in the event of a foreclosure by the Collateral Agent on any of the Collateral pursuant to a public or private sale or other disposition, the Collateral Agent or any Lender may be the purchaser or licensor of any or all of such Collateral at any such sale or other disposition and the Collateral Agent, as agent for and representative of the Secured Parties (but not any Lender or Lenders in its or their respective individual capacities unless the Required Lenders shall otherwise agree in writing) shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by the Collateral Agent at such sale or other Disposition.
189
MISCELLANEOUS
190
191
Without prejudice to the survival of any other agreements contained herein, indemnification and reimbursement obligations contained herein (including pursuant to Sections 2.15, 2.16, 2.17 and 10.05) shall survive the Termination Date.
192
For the purposes of this Section 10.04, “Approved Fund” shall mean any person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. Notwithstanding the foregoing or anything to the contrary herein, no Lender shall be permitted to assign or transfer any portion of its rights and obligations under this Agreement to (A) any Ineligible Institution, (B) any Defaulting Lender or any of its Subsidiaries, or any person who, upon becoming a Lender hereunder, would constitute any of the foregoing persons described in this clause (B), or (C) a natural person.
193
Notwithstanding the foregoing, each Loan Party and the Lenders acknowledge and agree that the Administrative Agent shall not have any responsibility or obligation to determine whether any Lender or potential Lender is an Ineligible Institution and the Administrative Agent shall have no liability with respect to any assignment made, or disclosure of confidential information in connection therewith, to an Ineligible Institution. Any assigning Lender shall, in connection with any potential assignment, provide to the Borrower a copy of its request (including the name of the prospective assignee) concurrently with its delivery of the same request to the Administrative Agent irrespective of whether or not an Event of Default under Section 8.01(b), (c), (h) or (i) has occurred and is continuing.
194
195
196
197
198
199
5 Effective Date), and, if necessary, the reasonable fees, charges and disbursements of specialty counsel for the Administrative Agent, the Collateral Agent and the Arrangers, taken as a whole, and one local counsel per relevant material jurisdiction for the Administrative Agent, the Collateral Agent and the Arrangers, taken as a whole), and (ii) all reasonable and documented out-of-pocket expenses incurred by the Agents or any Lender in connection with the enforcement of their rights in connection with this Agreement and the other Loan Documents, in connection with the Loans made or the Letters of Credit issued hereunder (but limited, in the case of legal fees and expenses, to the reasonable and documented out-of-pocket fees, charges and disbursements of a single counsel for all such persons, taken as a whole, and, if necessary, specialty counsel and a single local counsel in each relevant material jurisdiction for all such persons, taken as a whole (and, solely in the case of an actual or perceived conflict of interest where such person affected by such conflict informs the Borrower of such conflict and thereafter retains its own counsel with the Borrower’s prior written consent (not to be unreasonably withheld), of another firm of such for such affected person in each relevant jurisdiction)).
200
201
202
203
provided, further, that no such agreement shall amend, modify or otherwise affect the rights or duties of the Administrative Agent, Swingline Lender or an Issuing Bank hereunder without the prior written consent of the Administrative Agent, Swingline Lender or such Issuing Bank acting as such at the effective date of such agreement, as applicable. Each Lender shall be bound by any waiver, amendment or modification authorized by this Section 10.08 and any consent by any Lender pursuant to this Section 10.08 shall bind any Assignee of such Lender.
204
205
206
EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.11.
207
Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Loan Document shall affect any right that the Administrative Agent or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against the Borrower or any other Loan Party or its properties in the courts of any jurisdiction.
208
For the avoidance of doubt, nothing in the preceding paragraph shall prohibit any person from voluntarily disclosing or providing any information within the scope of the referenced confidentiality provision to any governmental, regulatory or self-regulatory organization (any such entity, a “Regulatory Authority”) to the extent that any such prohibition on disclosure set forth in such confidentiality provision shall be prohibited by the laws or regulations applicable to such Regulatory Authority.
209
210
211
212
Each of the other Loan Parties hereby appoints the Borrower as its agent for all purposes relevant to this Agreement and the other Loan Documents, including the giving and receipt of notices and the execution and delivery of all documents, instruments and certificates contemplated herein and therein and all modifications hereto and thereto.
213
Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States):
In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.
As used in this Section 10.25, the following terms have the following meanings:
214
[Signature Pages Intentionally Omitted]
215
Exhibit 31.1
CERTIFICATION
I, Stephen W. Beard, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Covista Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: May 7, 2026 |
/s/ Stephen W. Beard |
|
Stephen W. Beard |
|
Chairman and Chief Executive Officer |
|
(Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION
I, Robert J. Phelan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Covista Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: May 7, 2026 |
/s/ Robert J. Phelan |
|
Robert J. Phelan |
|
Senior Vice President and Chief Financial Officer |
|
(Principal Financial Officer) |
Exhibit 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Covista Inc. (“Covista”) for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of Covista certifies pursuant to 18 U.S.C. Section 1350, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Covista for the periods covered by the Report. |
Date: May 7, 2026 |
/s/ Stephen W. Beard |
|
Stephen W. Beard |
|
Chairman and Chief Executive Officer |
|
(Principal Executive Officer) |
|
|
Date: May 7, 2026 |
/s/ Robert J. Phelan |
|
Robert J. Phelan |
|
Senior Vice President and Chief Financial Officer |
|
(Principal Financial Officer) |